Abstract: Lifestyle factors, especially diet and nutrition, are currently regarded as essential avenues to decrease modern-day cardiometabolic disorders (CMD), including obesity, metabolic syndrome, type 2 diabetes, and atherosclerosis. Many groups around the world attribute these trends, at least partially, to bioactive plant polyphenols given their anti-oxidant and anti-inflammatory actions. In fact, polyphenols can prevent or reverse the progression of disease processes through many distinct mechanisms. In particular, the crosstalk between polyphenols and gut microbiota, recently unveiled thanks to DNA-based tools and next generation sequencing, unravelled the central regulatory role of dietary polyphenols and their intestinal micro-ecology metabolites on the host energy metabolism and related illnesses. The objectives of this review are to: (1) provide an understanding of classification, structure, and bioavailability of dietary polyphenols; (2) underline their metabolism by gut microbiota; (3) highlight their prebiotic effects on microflora; (4) discuss the multifaceted roles of their metabolites in CMD while shedding light on the mechanisms of action; and (5) underscore their ability to initiate host epigenetic regulation. In sum, the review clearly documents whether dietary polyphenols and micro-ecology favorably interact to promote multiple physiological functions on human organism.

Keywords: dietary polyphenols; metabolites; oxidative stress; inflammation; epigenetics; microflora; cardiometabolic complications

1. Introduction

Polyphenols, synthesized in a wide variety of fruits, legumes, and herbs, interestingly serve to protect against biotic and abiotic stresses caused by insects and parasites [1–3]. However, much attention is presently given to dietary polyphenols in view of their evident health benefits. These phenolic compounds are intrinsically strong free radical scavengers [4] and exhibit obvious potential in alleviating oxidative stress (OxS)-related illnesses. In this context, epidemiological and animal food intervention studies have established a solid association between the consumption of polyphenol-rich foods or beverages and their preventive influence on complex diseases, including insulin resistance (IR) [5–8], type 2 diabetes [9,10], obesity [11–13], and atherosclerosis [14].
Antioxidants 2020, 9, 982 2 of 50
diabetes (T2D) [9–12], obesity [5,9,13–16], cardiovascular diseases (CVD) [17–22], neurodegenerative
disorders [23–26], and cancer [22,27–29]. Recently, polyphenols have also been suggested as plausible
adjunctive therapeutic agents for the COVID-19-induced inflammatory storm [30–32].

The growing evidence as to the prevention and management of different disorders by dietary
polyphenols has led to multiple studies focusing on their dietary sources [33], efficacy [20],
and bioavailability [34–36]. However, much remains to be learned about their potential mechanisms of
action. In particular, their dynamic interaction with intestinal microbiota is of utmost importance as
~90% of the amount ingested reach the colon to directly influence microbial ecology and, at the same
time, undergo microflora-induced metabolic modifications [37,38]. These interactions represent the
specific topic of the present critical review. First, we will discuss the prebiotic action of polyphenols. Second, we will focus on their transformation and physiological impact on the gastrointestinal (GI) tract.
Third, we will emphasize the role of their metabolites resulting from their catabolism by colonic bacteria.
Fourth, we will analyze their cardiometabolic effects while highlighting their mechanisms of action and
underscoring epigenetic regulation. Clearly, the ultimate goal of this review is to show that the health
benefits of dietary polyphenols are through the action of their bioactive metabolites. Nonetheless, for
the reader’s understanding, it is essential to provide a brief introduction, which describes the structure,
classification, and bioavailability of polyphenols.

2. Polyphenols: Classification, Structure, and Bioavailability

2.1. Classification and Structure of Polyphenols

Concisely, polyphenols are characterized by at least one aromatic ring and one hydroxyl functional
group with evolving structure from a simple molecule to a complex polymer. They are classified into
flavonoids and non-flavonoids, according to the intricacy of their structure, number of phenol rings,
and carbon skeleton [32,39–41].

Flavonoids present a benzo-γ-pyrene structure containing two aromatic rings (A and B) bound by
a 3-carbon bridge (C6–C3–C6). Based on the differences in the C ring, flavonoids can be subdivided
into six sub-classes, namely: (1) flavonols (e.g., quercetin, kaempferol); (2) flavones (e.g., luteolin,
apigenin); (3) isoflavones (e.g., daidzein, genistein); (4) flavanones (e.g., naringenin, hesperetin);
(5) flavanols (e.g., catechins, epigallocatechins); and (6) anthocyanidins (e.g., malvidin, cyanidin).
Although polyphenols may be encountered in plants as aglycones, they are generally found as glycoside
derivatives, glucoside, galactoside, rhamnose, xyloside, rutinoside, arabinopyranoside, and finally
arabinofuranoside, being the most common [39]. Interestingly, the various tannin functional groups
(e.g., hydroxyls) allow them to create non-covalent (hydrophobic and hydrogen) bounds and covalent
bonds with proteins and carbohydrates [42–44]. Moreover, tannins are polyphenols that are most
involved in binding to proline-rich proteins [45].

2.2. Bioavailability of Polyphenols

2.2.1. Factors Affecting Polyphenol Absorption

Polyphenol bioavailability (e.g., alimentary proportion delivered to blood circulation) is dependent
on diverse conditions such as their stability, transport, and metabolic behavior. Several intrinsic and
extrinsic factors influence the content of plant polyphenols [35]. It is worth mentioning that their
relative composition and levels vary extensively among species and between varieties of the same
species in association with their genetic background and state of ripeness, which is related to the time
of harvest. For example, the content of olive secoiridoid phenolic derivatives decreased when irrigation
and ripening increased [35,46–48]. Furthermore, the concentration and variety of phenolic derivatives
depend on storage conditions as illustrated by the variability of the phenolic content and total
antioxidant capacity of 14 apple and 6 pear cultivars harvested at different periods [46]. The chemical
structure is another important intrinsic factor when considering bioavailability. Polyphenols vary
widely in molecular weight, secondary and tertiary structures, as well as glycosylation level [49–51]. For instance, resveratrol and quercetin glycosides are absorbed to a lesser extent than the respective aglycones, which influences their metabolic fate through the digestive tract, their absorption and release in the portal circulation, and excretion in urine or feces [52].

With regards to extrinsic aspects, short time storage at low temperature also affects polyphenol content as exemplified by the broccoli loss of its caffeoyl-quinic and sinapic acid contents [53]. Food processing is yet another external factor when considering polyphenol bioavailability. Thermal processing causes diverging effects on polyphenol content and absorption. For instance, Xu et al. [54] reported that thermal processing significantly decreased bean total phenolic content and antioxidant properties, while Khatun et al. [55] reported the opposite by documenting an increase in the same properties when heating spices. These dissimilarities may be explained both by the difference in polyphenol moieties, matrix, and cooking process. The role of the food matrix on the disposition of polyphenols should not be under-evaluated given the interaction between food components ingested simultaneously (fat, proteins, complex carbohydrates) and different polyphenolic compounds likely influencing their interaction with the microbiota and ultimately their absorption. In a rat model, the combination of lecithin and soya bean oil or emulsifiers (sucrose, fatty ester, polyglycerol fatty acid ester, and sodium taurocholate) increased intestinal absorption efficiency of water-dissolved quercetin when these constituents had no effect given separately [56]. Similarly, the administration of hydroxytyrosol as a sole natural product to humans or rats provides a better bioavailability than when combined with refined oil or yogurt, although its handling differed between the two species [57]. Differing digestive tract possesses such as luminal machinery, bile acid secretion, and enterohepatic cycle may explain the differences. The above examples suffice to warrant precautions when interpreting results obtained from different protocols. The several factors mentioned, and others have to be carefully taken into account when conducting studies using cellular models, animals, or clinical investigations, as they could explain variability in outcomes results from numerous reports. In general, polyphenols exhibit a low bioavailability with maximal plasma concentrations reached within 2 to 4 h post ingestion, and an apparent short elimination time with a return to baseline levels within 8 to 12 h [58]. Hence, 24 h-urine collections generally provide a more accurate evaluation of total polyphenol absorption, metabolism, and excretion [59]. These pharmacokinetic properties suggest that only long-term consumption of a variety of polyphenols will affect the health trajectory and support the role of the “Mediterranean diet” in improving population health perspectives.

2.2.2. Absorption of Polyphenols and Derivatives

Polyphenol intestinal absorption was indirectly estimated by raised antioxidant defense in the circulation in response to their consumption. The basic principles for their transport and local metabolism are partlyway established. Figure 1 schematizes the digestion and absorption processes as generally accepted today for polyphenols. Distinction must be made between the digestive and absorption processes of low and high molecular weight polyphenols along the digestive tract as the sites and the efficacy may differ. In decreasing order of absorption kinetics, isoflavones, caffeic and gallic acids lead, followed by catechins, flavanones, and quercetin glucosides. High molecular weight polyphenols such as proanthocyanidins, galloylated catechins, and anthocyanins come last [60]. For instance, the degree of polymerization of procyanidins (dimer B3, trimer C2, and polymers), isolated from willow tree catkins, decreased their absorption through the rat gut barrier and can limit their metabolism by the intestinal microbiota when compared to catechins [61].
Figure 1. Integrated view of intestinal dietary polyphenol absorption, luminal transformation, and actions of their relevant metabolites on cardiometabolic disorders. As dietary polyphenols have limited absorption in the stomach and the small intestine, the unabsorbed polyphenols continue their transit to the colon where they are hydrolyzed, demethylated, decarboxylated, dehydroxylated, and ring fissioned by microbiota. Following these processes, microbial metabolites are subjected to phase II metabolism in the colon and liver, and enter the bloodstream to exert their biological effects, which extend to peripheral organs. Unabsorbed polyphenols and metabolites are excreted in feces, and absorbed microbial metabolites are mostly excreted in the urine. Noteworthy, whereas polyphenols improve microbiota composition, diversity and functions through their prebiotic actions, gut microbiota transform them into efficient bioactive regulators capable of optimizing cardiometabolic health in healthy individuals, while alleviating and mitigating the metabolic syndrome in patients. *Created with Servier Medical Art (A service to medicine provided by Les Laboratoires Servier, 50, rue Carnot—92284 Suresnes Cedex—France.

2.2.3. Gastric Uptake

It is well established that plant polyphenols predominantly present as glycosides undergo deglycosylation to their respective lipophilic aglycones, thereby enhancing their absorption through the GI [62,63]. Whether the stomach plays a significant role remains uncertain until today. To our knowledge, there is little direct in vivo evidence on the contribution of the human stomach to the assimilation of phenolic compounds. It needs to be underlined that in vitro simulation or animal models are the most common sources of information. Table 1 summarizes the results obtained in in vitro and in vivo models as well as in humans.
Table 1. Gastric handling of polyphenols.

| Substrates                        | Sources               | Experimental Conditions and Model                                                                 | End Products                     | Main Observations                           | Conclusions                                                                 | Ref |
|-----------------------------------|-----------------------|---------------------------------------------------------------------------------------------------|----------------------------------|--------------------------------------------|----------------------------------------------------------------------------|-----|
| Procyanidins polymers (2–6 mers)  | Cocoa                 | Incubation in simulated gastric juice (pH 2.0) at 37 °C for up to 3.5 h                           | Catechin/epicatechin Monomer and dimer | Time-dependant hydrolysis of oligomers.    | Role of stomach in the processing of phenolic compounds.                      | [64]|
| Dimeric catechin/ epicatechin     | Cocoa                 | Incubation in simulated gastric juice (pH 1.8) at 37 °C for up to 60 min                          | Catechin/epicatechin Dimers isomerization | Time-dependant hydrolysis of dimers.      | Role of stomach in the processing of phenolic compounds.                      | [65]|
| Free and conjugated Hydroytyrosol and Tyrosol | Olive oil            | Incubation in simulated gastric juice (pH 2.0) at 37 °C for up to 4 h                           | Free hydroxytyrosol and tyrosol | Time-dependent hydrolysis of hydroxytyrosol and tyrosol conjugates. | Stomach hydrolyzes phenolic compounds conjugates.                           | [66]|
| Monomeric/ Polymeric Catechin/ epicatechin | Grape seed extract | Incubation in simulated gastric juice (pH 2.0) + pepsin at 37 °C for 2 h                      | Catechin/epicatechin Oligomers | Stability of catechin/epicat.             | Stability of phenolic compounds at the gastric level.                       | [67]|
| Hydroxycinnamic acid derivatives, Flavonols, dihydrochlcones monomeric flavans-3-ols, procyanidin B2 | Apple juice          | Incubation in simulated gastric juice (pH 2.0) + pepsin at 37 °C for up to 4 h                  | Hydroxycinnamic acid derivatives, flavonols, dihydrochlcones monomeric, Epicatechin monomer | Stability of Hydroxycinnamic acid derivatives, flavonols, dihydrochlcones monomeric. Hydrolysis of procyanidin B2 | Stability of phenolic compounds in the stomach dependent on structure. | [68]|
| Purified Hesperidin 2S | Citrus sinsensis peel extract | Digestion in the simulator of human intestinal microbial ecosystem (pH 2.0). | Intact hesperidin 2S | No degradation of Hesperidin 2S. | Hesperidin is resistant to the degradation in the stomach.                     | [69]|
| Resveratrol caprylic esters | Synthesis product | Incubation in simulated gastric juice (pH 1.2) + pepsin at 37 °C for up to 2 h. | Intact resveratrol caprylic esters | No hydrolysis of resveratrol caprylic esters. | Resveratrol caprylic esters are not metabolized in the gastric phase.          | [70]|
| Substrates                        | Sources                          | Experimental Conditions and Model                                                                 | End Products                                                                 | Main Observations                                                                                                                                                                                                 | Conclusions                                                                                                                                                                                                 | Ref |
|----------------------------------|----------------------------------|---------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Polyphenols                      | Simulated oral digestion of peeled apple tissue | Incubation in simulated gastric juice (pH 1.6) + pepsin at 37 °C for up to 1 h in a dynamic rat stomach wall model | Released from initial material in deceasing order: chlorogenic acid, epicatechin, catechin, procyanidin B<sub>2</sub> flavan-3-ols, hydroxycinnamic acids, dihydrochalcones flavonols. | All polyphenols were stable except for procyanidin B<sub>2</sub> that was hydrolyzed to epicatechin.                                                                                                                                   | Polyphenol resistance to degradation dependent on structure.                                                                                                                                                  | [71]|
| Polyphenols                      | Simulated oral digestion of Kiwifruit tissue | Incubation in simulated gastric juice (pH 1.2) + pepsin at 37 °C for 2 h                          | Release of the 16 identified polyphenols from initial material during stomach digestion: catechin, epicatechin, quercetin, rutin, chlorogenic acid, caffeic acid, ferulic acid, p-coumaric acid, gallic acid, salicylic acid, vanillic acid. | All polyphenols were stable.                                                                                                           | Polyphenol resistance to degradation.                                                                                                                                                                         | [72]|
| Procyanidins oligomers and flavonol monomers | Cocoa                            | Oral administration of procyanidin oligomers and flavonol monomers to healthy subjects. Gastric contents collected and analyzed at 20 min. | Intact procyanidins oligomer and flavonol monomer profiles similar to original product. | Procyanidins oligomers and flavonol monomers are stable in the gastric environment.                                                                                                                                                                                                 |                                                                                                                                                                                                         | [73]|
| Caffeic acid, gallic acid, chlorogenic acid, ferulic acid, coumaric acid | Purchased purified phenolic acids | In vivo rat ligated pylorus model for in situ gastric digestion at 37 °C for 25 min. Portal vein and abdominal aorta blood collected. Plasma analyzed with and without sulfatase and β-glucuronidase treatment. | Intact and conjugated coumaric acid, ferulic acid, caffeic acid, gallic acid, chlorogenic acid | Rapid appearance of coumaric acid > ferulic acid > caffeic acid > gallic acid > chlorogenic acid in portal vein and abdominal artery. Rapid appearance mainly of coumaric and ferulic acid conjugates in portal vein and abdominal artery. | Differential absorption efficiency of phenolic acids and differential affinity of monocarboxylic acid transporters.                                                                                     | [74]|
| Substrates                                                                 | Sources                | Experimental Conditions and Model                                                                 | End Products                                                                 | Main Observations                                                                 | Conclusions                                                                 | Ref  |
|----------------------------------------------------------------------------|------------------------|---------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------------|------------------------------------------------------------------------------|------|
| Flavone glycosides (apigenin, luteolin, chrysoeriol) and flavonoid glycosides (kaempferol, quercetin, isorhamnetin) | Parsley                | Oral administration of glycoside extracts to rats. Animals sacrificed at 1, 1.5, 2, 4, or 12 h post administration. GI tract segmented (stomach, small intestine, colon, cecum). Stomach wall and lumen content analyzed at 2 h. | At 2 h: flavonoid glycosides in the stomach lumen and wall. Quercetin aglycone in the stomach wall. | At 2 h: flavonoid composition of stomach wall similar to stomach lumen but concentration lower. One aglycone present. | Stomach absorbs intact flavonoid glycosides.                                  | [75] |
| Isoflavones (Daidzein, daidzin, genistein, and genistin)                   | Commercial source      | In vivo rat ligated pylorus model for in situ gastric digestion at 37 °C for 25 min. Jugular vein blood analyzed for daidzein, daidzin, genistein, and genistin up to 30 min. | Daidzein and genet ein (iso flavone aglycones)                               | Time-dependent absorption and transport of Daidzein and genet ein, but not their respective glycosides daidzin and genistin. | Selective absorption and transport of isoflavone aglycones by the stomach.    | [76] |
| Quercetin, rutin, and isoquercetin                                         | Commercial source      | In vivo rat ligated pylorus model for in situ gastric digestion at 37 °C for 30 min. Biliary duct cannulation and content analyzed. Aortic blood collected and analyzed. | Biliary quercetin and 3′-O-methyl-quercetin                                  | Quercetin absorbed by the stomach and secreted in bile. No absorption of rutin or isoquercetin. | Limited role of the stomach in flavonoid glycosides. Selective absorption and transport of aglycones. | [77] |
Purified cocoa procyanidin oligomers, incubated in simulated gastric juice, led to the appearance of dimers and monomers in a time-dependent fashion [64,65]. Similarly, olive oil polyphenol glycosides, including oleuropein (glycoside of elenolic acid linked to hydroxytyrosol) underwent rapid and time-dependent hydrolysis, yielding appreciable amounts of free hydroxytyrosol and tyrosol, probably through nucleophilic attack [66]. On the contrary, other studies, using the same in vitro model, along with oral administration of polyphenols to humans, showed stability of a variety of polyphenols in the acidic milieu [67–73]. Interestingly, the incubation of apple phloretin and quercetin for 5 min with native saliva resulted in the production of the respective aglycones, likely by oral bacterial flora as the process was blocked by antibiotics [68]. In the same study, hydroxycinnamic acid derivatives, flavonols, dihydrochalcones, and monomeric flavan-3-ols were stable when incubated with simulated gastric juice at pH 1.8, but procyanidin B2 was degraded. Obviously, the in vitro models suffer from being an inadequate reflection of the gastric fluid, which lacks mucus normally secreted by parietal cells. This is supported by the notable stability of cocoa procyanidin polymers in vivo in the human stomach environment [73]. In terms of in vivo studies, the in situ digestion rat pylorus ligated model shows that polyphenol aglycones are absorbed by the stomach, and suggests the limited role of the stomach in flavonoid glycosides metabolism [74–77]. These results reveal inequality in the behavior of polyphenols in different experimental models and warrant careful analysis to obtain a complete representation.

2.2.4. Small Intestine Uptake

Duodenum

Using the in vitro three-step model simulating the digestive process from the mouth to the small intestine [78], it was shown that the duodenal digestion phase either with static or continuous-flow cellulose membrane-based dialysis containing bile salts and pancreatin resulted in dialyzable (chyme-available for passive absorption into the systemic circulation) and non-dialyzable (digested fraction available for colon) fractions [79]. Profiling the chyme and the non-dialyzable procyanidin content of cocoa liquor post gastric digestion revealed that the high-molecular weight procyanidins (pentamers to nonamers) were hydrolyzed essentially into monomers and dimers. Similar profiles were observed for the duodenal digest. Interestingly, the cocoa liquor duodenal digest contained much higher procyanidin concentrations than the cocoa powder counterpart that the authors attributed to the protective effect of fat micellar structures present in the liquor. More recently, using the same dynamic duodenal model, most of the intact procyanidins isolated from chocolate nibs were retained in the non-dialyzable fraction, which would likely be available for colonic digestion by the microbiota, while smaller molecular weight dimers and trimers were quantified in the dialyzable fraction [67]. On the other hand, the addition of carbohydrate-enriched food resulted in lower duodenal digestibility of procyanidin. Last, with the ex vivo reverted duodenal sac model, the bioavailability of curcumin was found to be significantly enhanced when encapsulated in low- and high-molecular weight polylactic-co-glycolic acid nanoparticles, possibly attributable to faster dissolution following the administration [80]. Overall, these results underpin the effect of the food matrix on the metabolism of polyphenols.

Jejunum and Ileum

It is well known that under physiological conditions, the small intestine, particularly the jejunum and ileum segments, represents the principal location for the digestion and absorption of dietary lipids. This holds for polyphenols, although with differing efficiency according to their molecular weight and type of glycosylation. Upon reaching the jejunum and ileum, glycosylated polyphenols are either hydrolyzed into their respective aglycones by the membrane-bound brush-border lactase phlorizin hydrolase [81] or transported intact by the enterocyte sodium-glucose co-transporter and hydrolyzed by the cytosolic β-glucosidase [82–84]. The nature of carbohydrate moieties affects the absorption of polyphenols through the small intestine. For instance, whereas glucoside conjugates and their aglycones
are absorbed in the small intestine, those containing rhamnose molecules, [e.g., the flavonols hesperidin (hesperidin-7-O-glucosyl-rhamnose) and rutin (quercetin-3-O-glucosyl-rhamnose)], must proceed to the colon where rhamnose will be removed by bacterial rhamnosidase [85]. On the other hand, catechin and epicatechin, monomers of the flavonol family, which are often acylated by gallic acid, are readily absorbed by enterocytes without any deconjugation or hydrolysis [86,87].

Caco-2 cells, a human colon carcinoma derived cell line, which upon confluence develops enterocyte-like characteristics, have extensively been used as a model for studying lipid and drug metabolism [88] and transport [89]. They also have served as a model for studying the absorption, transport, and metabolism of polyphenols as detailed in Table 2.

Caco-2 cells have been shown to absorb major dietary hydroxycinnamates and diferulates after de-esterification (phase 1 transformation) and conversion into glucuronate, methyl, and sulfate conjugates (Phase 2 transformation) [90]. In 2006, Corona et al. [66] reported that Caco-2 cells transported hydroxytyrosol from the apical to the basolateral compartment, with the appearance of 3-O-methyl–hydroxytyrosol and glutathionyl-hydroxytyrosol in both compartments. They observed a similar transport for tyrosol, without any evidence of further metabolism or transport for oleuropein. The same year, trans-epithelial transport of trans-piceid (3-β trans-resveratrol glucoside) and deglycosylation in trans-resveratrol were reported using human intestinal Caco-2 cell monolayers [82]. The important question in the context of nutrition is whether polyphenols behave similarly when evaluated as single compounds as when assessed in complex mixtures [93,94]. Su et al. [92] partially answered this question by showing that, in Caco-2 cells, (+)-catechin significantly enhanced the cellular uptake and transport of the isoflavone daidzein-8-C-glucoside, whereas this compound significantly abated that of (+)-catechin, and that inhibition of efflux pumps increased their uptake. Although valuable for screening polyphenol bioavailability, caution should be used when interpreting the data obtained from the Caco-2 cellular model in terms of predictability. Indeed, even if in vitro smaller phenolic derivatives of hesperidin 2S were absorbed, hesperidin conjugates were the main bioavailable moieties in a randomized human controlled study [69].

The intestinal porcine enterocyte cell line (IPEC), a non-transformed non-tumorigenic permanent intestinal cell line derived from the jejunum is another model that merits attention for two main reasons. First, it maintains its differentiated characteristics, and second, there is a close analogy in results obtained in vivo with the porcine model, the closest to the human GI system [95,96]. To our knowledge, it has seldom been used to study polyphenol absorption. However, a good correlation for the uptake of grape pomace polyphenols was observed between IPEC cells and the duodenum and colon of piglets [97]. In addition, Wan et al. [98] proved functionality of the same in vitro model by showing enhanced the secretion of α-defensins-1 and 2 and reduced the E. coli translocation across a confluent IPEC cells by epigallocatechin-3-gallate, the major polyphenol specie in green tea.
Table 2. Experimented Caco-2 cells in polyphenol transport and metabolism.

| Substrates                              | Sources            | Experimental Conditions                                                                 | Main Observations                                                                                     | Conclusions                                                                                           | Ref  |
|-----------------------------------------|--------------------|----------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------|------|
| Hydroxytyrosol, tyrosol, and oleuropein | Olive oil          | Polyphenols added to the apical chamber and incubation for 2 h. Apical and basolateral compartments collected and analyzed. | ↓ hydroxytyrosol and tyrosol in the apical and ↑ in the basolateral media. Appearance of 3-O-methyl-tyrosol and glutathionyl-hydroxytyrosol in the apical and basolateral compartments. Φ transport of oleuropein from the apical to the basolateral compartment. | Hydroxytyrosol transported through the enterocyte apical membrane to the basolateral compartment with formation of conjugates. | [66] |
| Trans-piceid (Resveratrol 3-β-mono-D-glucoside) | V. Vinifera       | Incubation with trans-piceid up to 360 min.                                              | Bidirectional (apical to basolateral and inverse) transport of trans-piceid. Detectable trans-resveratrol in both chambers. | Trans-piceid and its aglycone are transported across the apical side and effluxed by the basolateral membrane. | [82] |
| Trans-piceid (Resveratrol 3-β-mono-D-glucoside) | V. Vinifera       | Pre-incubated with ± chrysin (5,7-Dihydroxyflavone) and ± n-saccharic lactone in 6-well plates. Incubated with trans-piceid or trans-resveratrol 24 h. | Appearance of trans-Resveratrol after incubation with trans-piceid. ↑ trans- resveratrol-glucuronides production in chrysin (UDP-glucuronosyl transferase inducer) treated cells. | Trans-piceid undergoes hydrolysis to its aglycone and trans-resveratrol undergoes phase II metabolism within the enterocyte. | [82] |
| Quercetin, Quercetin-4-O-β-D-glucoside, Quercetin-3-O-β-D-glucoside, Quercetin-3,4-di-O-β-D-glucoside | Purified polyphenols | Polyphenols added to the apical chamber and incubation up to 2 h. Apical, cellular, and basolateral compartments collected. | Time-dependent ↓ quercetin in apical chamber. Stability of quercetin glycoside in apical chamber. Time-dependent appearance of quercetin glycosides in apical chamber and cellular compartment when quercetin is added. Time-dependent ↑ quercetin glycosides in basolateral compartment and stable low quercetin. | Quercetin aglycone is preferentially transported through the enterocyte apical membrane to the basolateral compartment after intracellular conjugation. | [84] |
| Substrates                                                                 | Sources                                | Experimental Conditions                                                                 | Main Observations                                                                                                                                                                                                 | Conclusions                                                                                                                                                                                                 | Ref |
|----------------------------------------------------------------------------|----------------------------------------|----------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| Catechin, epigallocatechin gallate encapsulated or not in non-ionic surfactant-based vesicles (niosomes) | Purified polyphenols                   | Polyphenols added to the apical chamber and incubation up to 6 h at 37 °C or 4 °C. Cell and basolateral compartments collected and analyzed. | Time-, concentration-, and temperature-dependent uptake of polyphenols. ↑ uptake when inserted into niosomes. Time-, concentration-, and temperature-dependent transport of polyphenol to the basolateral compartment, ↑ with niosomes. ↓ transport with ATP inhibitor, ↑ transport with EDTA and P-glycoproteins and multidrug resistance proteins inhibitors. | Temperature dependence of uptake suggested energy-driven process. Deactivation of efflux pumps resulted in increased uptake by apical membrane and efflux in basolateral compartment. | [86] |
| Free and methyl esters of Hydroxycinnamic acids (ferulic, sinapic, p-coumaric and caffeic methyl esters), Ethyl esters of 5,5-diferulate, 8-O-4-diferulate, 8,5-benzofuran | Purified polyphenols                   | Medium collected after 24 h incubation and analyzed.                                   | Glucuronides of ferulic, sinapic, p-coumaric and caffeic methyl esters, sulfates of ferulic, sinapic, p-coumaric and caffeic methyl esters, ferulic, sinapic, p-coumaric sulfates.                                      | Metabolites produced either intra-cellularly and excreted in medium or produced in the medium by secreted phase I and phase II enzymes.                                                                | [90] |
| Quercetin, Quercetin-3,7,3,4-O-tetra-ethylacetate                          | Purified polyphenols                   | Polyphenols added to the apical (A) or basolateral (B) chamber and incubate up to 2 h. Apical, and basolateral compartments collected.                | Time- and temperature-dependent bidirectional but preferential B-A transport of quercetin and ethylacetate derivative. Transport more efficient for the ethylacetate derivative. P-glycoproteins and multidrug resistance proteins inhibitors. ↑ quercetin permeation coefficient from A-B and ↓ from B-A. Φ on ethylacetate derivative. | Quercetin might be a substrate of P-glycoproteins and multidrug resistance proteins, causing the ↓ bioavailability of quercetin. Quercetin ethylacetate derivative exhibited better membrane permeation than parent compound. | [91] |
Table 2. Cont.

| Substrates                        | Sources                     | Experimental Conditions | Main Observations                                                                 | Conclusions                                                                 | Ref  |
|-----------------------------------|-----------------------------|-------------------------|----------------------------------------------------------------------------------|------------------------------------------------------------------------------|------|
| Catechin, puerarin (Daidzein-8-C-glucoside) | Purified polyphenols        | Incubation up to 2 h.   | Time- and concentration-dependent uptake. Catechin enhanced uptake and transcellular transport of puerarin but puerarin inhibited that of catechin. P-glycoproteins and multidrug resistance proteins inhibitors. ↑ polyphenol uptake and transport. | Deactivation of efflux pumps resulted in increased uptake by apical membrane and efflux in basolateral compartment. | [92] |

↑: increase; ↓: decrease; Φ: no effect.
Colon

The case of the colon bears some singularity in the sense that there is a reciprocal relationship between polyphenols and colonic microbiota. It has been clearly established that the gut microbiome is a key actor in modulating the production, bioavailability, and biological activities of complex low molecular weight phenolic metabolites grouped under the term polyphenol metabolome [99,100]. Rarely, the transport of polyphenols by the colon has directly been evaluated as most of the studies employed intestinal cell models displaying features of the small intestine [101]. It is, however, worthy to mention that T84 colon carcinoma cell line monolayers, incubated with ferulic, isoferulic, cinnamic, and hydroxycinnamic acids, as well as with flavonoids, showed appreciable transport from the luminal to the basolateral side [102]. Measurable levels of ferulic glucuronide and sulfate were detected in the apical and basolateral compartments when supplied at supra-physiological concentrations. Other reports bear mostly on the polyphenol anticancerogenic properties without addressing the uptake and transport per se [103–106].

The enterohepatic cycle is an important mechanism for the bioavailability and disposition of polyphenol aglycones and their metabolites. This is true whether absorbed by the small intestine or the colon (where they undergo in situ phase II enzymatic conversion to their respective methyl, glucuronide, and sulfate conjugates) or delivered to the liver via the portal circulation for further conjugation (before entering the blood stream and being excreted in urine). Alternatively, they enter the bile duct where mixed with bile salts, re-enter the small intestine for either a second-round absorption by enterocytes and transport to the liver, or excretion in the stools [37,107–109].

3. Interaction between Polyphenols and the Colon Microbiota

Humans are colonized by a wide array of microorganisms referred to as the microbiota that consists of obligate and facultative anaerobes, mainly targeting the colon [110,111]. Their main assignment is to provide assistance to their host in digesting food complex polysaccharides and proteins unprocessed in the upper GI tract [112]. The saccharolytic pathway, mainly active in the proximal colon, yields short chain fatty acids, of which acetic, propionic, and butyric acids are the most abundant, as well as lactic acid, CO₂, methane, and ethanol. The second catabolic pathway responsible for protein fermentation, mainly present in the distal colon, leads to metabolite species such as ammonia, various amines, thiols, phenols, and indoles [113,114]. The healthy gut ecosystem consists of the anaerobes Bacteroidetes and Firmicutes, the latter contributing to more than 90% of the total bacterial species, and Proteobacteria, Verrucomicrobia, and Actinobacteria accounting for the balance [115].

Diet composition has a definite role in the taxonomic and functional profile of the colon microbiota. For example, several reports have shown that high carbohydrate and fiber intakes are related to higher abundance of 3 enterotypes: Lachnospiraceae, Ruminococcaceae, and Bifidobacteria [116–118]. For their part, omnivorous women were shown to have a higher abundance of fecal butyrate producing taxa (Clostridium cluster XIVa and Roseburia/Eubacterium) than vegetarians [119]. Intervention studies have also established that changing from a carnivorous diet to a plant-based diet resulted in a gradual decrease in abundance of Bacteroides, a bile-tolerant symbiotic microorganism, and an increase in Firmicutes that preferentially metabolizes plant polysaccharides [120]. Furthermore, population food tradition-related differences in microbiota constitution have been reported; those consuming meat-based diets had higher abundances of Bacteroides than those traditionally consuming plant-based diets [118,121]. A controlled 10-week-diet intervention, involving overweight volunteers, demonstrated a rapid modification in microbiota species composition despite the inter-individual variation in initial composition [122]. Overall, the results indicate that Bacteroides, together with Alistipes and Parabacteroides, may be the primary proteolytic taxon in the human colon [112].
3.1. Polyphenol–Microbiota Interaction

Of interest, although still poorly understood, evidence is accruing on the influence of dietary polyphenols, perceived as xenobiotics, on the modulation of the colonic microflora and health [123]. They interfere with bacterial cell-to-cell communication and coordinate pathogenic behaviors, two clinically important characteristics with regards to virulence control and wound healing [124,125]. They also sensitize bacteria to xenobiotics and alter membrane permeability. This is exemplified by the sensitization of methicillin-resistant *Staphylococcus aureus* to β-lactam through the (−)-epicatechin gallate-mediated alterations of the bacterium cell wall bilayer, and enhanced release of lipotechoic acid from the cytoplasmic membrane [126]. Polyphenols, acting as prebiotics, have also been shown to modulate gut metabolism and immunity as well as inflammatory pathways through the change of T-cell functions, inhibition of mast cell degranulation, and down regulation of inflammatory cytokine responses [127–130]. Studies in animals and in humans have shown modification of colon microflora by polyphenolic compounds, resulting in growth inhibition of certain bacterial groups while permitting others to flourish [131–133]. Valuable effects of polyphenols, such as those present in red wine, include among others, enhanced abundance of beneficial bacterium taxa such as *Bifidobacterium* and *Lactobacillus*, capable of improving gut barrier protection, *Faecalibacterium prausnitzii* having anti-inflammatory properties, and *Roseburia* as a butyrate producer. Interestingly, the proliferation of these bacteria occurred at the expense of the less desirable *Escherichia coli* and *Enterobacter cloacae* [134]. Most of the important biological actions resulting from phenolic compounds and microbiota are depicted in Figure 2.

3.2. Impact of Microbiota on Polyphenol Metabolism

The transformation of polyphenols into bioactive metabolites is tributary to the colonic microflora species. For example, the Firmicutes: *Eubacterium ramulus* and oxidoreducens, *Clostridium orbiscidens* and *Flavonifractor plautii* metabolize the flavonols Kaempferol, Quercetin, and Myricetin by O-deglycosylation and C-ring fission into a series of metabolites comprising protocatechuic, 2-(3,4-dihydroxyphenyl)-acetic, 2-(4-hydroxyphenenil)-propionic, 3-hydroxyphenylacetic, 3-(3-Hydroxyphenyl)-propionic, 2-(3-hydroxyphenenil)-acetic, 2-(3-dihydroxyphenil)-acetic, and 3-(3,4-dihydroxyphenil)-acetic acids as well as short-chain fatty acids (SCFAs) [83,135,136] (Figure 2). Furthermore, *Enterococcus casseliflavus* (Firmicutes) hydrolyzes sugar moieties from quercetin-3-O-glucoside, a process releasing the aglycone and ultimately producing lactic, formic, and acetic acids, together with ethanol [137]. The Actinobacteria: *Slackia equolificiens*, *Slackia isoflavoniconvertens*, *Eggerthella lenta*, *Adlercreutzia equolificiens*, and *Bifidobacterium* spp metabolize the flavonones Naringenin and Hesperidin through C-ring fission yielding 3-(4-hydroxyphenyl)-propionic, 3-phenylpropionic and hydroxyphenylpropionic acids [135,136]. *Adlercreutzia equolificiens*, *Paraeggerthella hongkongensis*, *Slackia equolificiens*, *Slackia isoflavoniconvertens*, *Bacteroides ovatus*, *S. intermedius*, *R. productus*, *E. sp. Julong*, *E. faecium EPI1*, *L. mucosae EPI2*, and *F. magna*, have also been shown convert some the isoflavone daidzein to (S)-equol, a nonsteroidal estrogen-like molecule [[(3S)-3-(4-hydroxyphenyl)-7-chromanol]] [108,137].
4. Polyphenols and Metabolic Syndrome

The polyphenol metabolites, produced by the gut microbiota once absorbed and directed to the target tissues and organs, contribute to the metabolic health, through their antioxidant and anti-inflammatory properties, by preventing or reducing the risk of developing several cardiometabolic disorders (CMD), notably the metabolic syndrome (MetS).

The increasing prevalence of childhood MetS along with overweight and obesity is a major public health concern in both developed and developing countries. MetS is a key risk factor for the development of T2D, non-alcoholic fatty liver disease, and CVD in early adulthood [138–140]. MetS is a cluster of interrelated risk factors, including abdominal obesity, dyslipidemia, hypertension, hyperglycemia, and IR, which is triggered by cellular redox imbalance and inflammation as cardinal features [141–143].

In the last two decades, strategies to limit the deleterious effects of the MetS have been focused on diet regimen containing natural fruits, green vegetables, whole grains, legumes, probiotics, vitamin C, vitamin E, and ω-3 polyunsaturated-fatty acids [20,144–148]. Likewise, prebiotics, including polyphenols with their prebiotic potential, have also demonstrated promising effects on IR, glycemia, lipid profile, and CVD [8,134,149]. Other multiple studies, involving animal models, have consistently shown that administration of polyphenols, extracted from various sources, increased insulin sensitivity (via measurement of homeostatic model assessment for insulin resistance index, glucose intolerance, or insulin tolerance tests) and decreasing circulating free-fatty acid, triglyceride, cholesterol, C-reactive protein, resistin, and leptin concentrations [150–154]. At the clinical level, a parallel, double-blinded controlled and randomized 6-week dietary intervention demonstrated that strawberry and cranberry polyphenols improved insulin sensitivity in overweight and obese nondiabetic, insulin-resistant human subjects [8]. There was not a significant improvement of other cardiometabolic risk factors, which is probably due to the length of the intervention. Nevertheless, these in vivo results show the potential clinical preventive and therapeutic impact
of polyphenols on human diseases. Considering that impaired redox potential and inflammatory processes are the basis of MetS, polyphenols, identified for their antioxidant and anti-inflammatory properties [155,156], appear as suitable candidates for preventing its development. The review of the mechanisms linking polyphenols and alleviation of these features follows.

4.1. Antioxidative Effects of Polyphenols

Polyphenols are known as major contributors to the fruit total antioxidant activity [157]. They do so by donation of an electron or hydrogen atom to reactive oxygen, nitrogen, and chlorine species based either on hydrogen atom transfer or single electron transfer by proton transfer [158]. Reacting with the inner side of the plasma membrane hydrophobic compounds, polyphenols impede lipid and protein oxidation, thus protecting the structure, fluidity, and function of the cell membrane [159]. Polyphenols also chelate transition metals as Fe$^{2+}$, thus directly reducing the Fenton reaction and preventing oxidation by highly reactive hydroxyl radicals [160].

Reactive oxygen species (ROS) play leading roles in provoking pan-cellular inflammation. Their action is mediated by the activation of powerful transcription factors such as nuclear redox factor-2 (Nrf2), nuclear factor-kappa B (NF-$\kappa$B), and activator protein 1 [161]. Under unstressed conditions, inactive Nrf2 is linked to its cytoplasmic regulator actin-anchored Kelch-like ECH-associating protein 1. Due to reactive species accumulation in cells under OxS, Nrf2 dissociates from Kelch-like ECH-associating protein 1, translocates into the nucleus where it modulates antioxidant-responsive elements-mediated transcription cytoprotective genes [162,163]. Phenolic compounds are able to enhance protective pathways by activating Nrf2. For example, flavonoids induce Nrf2 translocation to the nucleus where it forms heterodimers with the leucine zipper-like transcription factors small musculo-aponeurotic fibrosarcoma proteins, then bind to antioxidant-responsive elements to activate target genes such as Phase II enzymes involved in detoxification [164]. In addition, Zhang et al. [165], using human breast cells, hepatic human liver cancer cells, and mouse Hepa-1 cells, demonstrated cell-dependent agonist/antagonist effects of several flavonoids on the regulation of aryl-hydrocarbon receptor-mediated signalling pathways. Polyphenols may also suppress pro-oxidative response by down-regulating the synthesis of the pro-inflammatory interleukin-(IL)-1$\beta$, tumor necrosis factor-alpha (TNF$\alpha$), and interferon-gamma. They do so by modulating NF-$\kappa$B and mitogen-activated protein kinase signaling pathways [166]. Moreover, phenolic compounds can display genoprotective effects, thereby preventing/reversing the progression of various CMD diseases [167]. Through the protection of DNA against OxS damages, some types of polyphenols can promote metabolic health [168–171]. For example, epigallocatechin gallate and resveratrol exhibit high capacity to decrease DNA double strand breaks, chromosome loss, and DNA deterioration response in $H_2O_2$-induced genotoxicity in cells [172,173]. A human supplementation trial has also shown the ability of green tea polyphenolic antioxidants to increase the resistance of DNA to oxidation damages [174].

4.2. Anti-Inflammatory Effects of Polyphenols

The crosstalk between oxidative and inflammation signalling pathways is important for cell homeostasis and survival. Indeed, overproduction of ROS has been shown to stimulate the release of pro-inflammatory cytokines. Reciprocally, NF-$\kappa$B controlled genes are able to regulate ROS production [175,176]. Various studies, particularly those oriented toward cancer, revealed that polyphenols are able to control chronic inflammatory responses at the level of cytokine production, NF-$\kappa$B-mediated gene expression, and the release of the tumor-suppressing transforming growth factor-beta [177–179].

Furthermore, closely related to the MetS, our group has more recently demonstrated, in post-confluent Caco-2/15 cells, that polyphenols extracted from dried apple peels (DAPP), containing phenolic acids, flavonol glycosides, flavan-3-ols, and procyanidins prevented iron-ascorbate-mediated lipid peroxidation and counteracted lipopolysaccharide-mediated inflammation as shown by the down regulation of the cytokines TNF$\alpha$ and IL-6, lessening of
cyclooxygenase-2 expression, and production of prostaglandin E\textsubscript{2} via the decline of NF-\kappaB. Concomitantly, the alleviation of inflammation was accompanied by the induction of Nrf2 (orchestrating cellular antioxidant defenses and maintaining redox homeostasis) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (the “master controller” of mitochondrial biogenesis) [180]. We later demonstrated that DAPP prevented and alleviated dextran sodium sulfate-induced intestinal inflammation in mice, stimulated antioxidant transcription factors, and improved mitochondrial dysfunction. They also decreased lipid peroxidation and up-regulated antioxidant enzymes, while decreasing the activity of myeloperoxidase, the expression of cyclooxygenase-2, and the production of prostaglandin E\textsubscript{2}. Moreover, DAPP partially restored mitochondrial redox homeostasis, fatty acid \(\beta\)-oxidation, ATP synthesis, apoptosis, and regulatory mitochondrial transcription factors [181]. As DAPP in parallel decreased the relative abundance of \textit{Peptostreptococcaceae} and \textit{Enterobacteriaceae} bacteria [182], it is possible that the modifications of intestinal microbiota brought about the amelioration of oxidative and inflammatory processes.

4.3. Epigenetic Control of Polyphenols

Epigenetic modification of gene expression is extremely important in the modulation of the OxS and inflammatory pathways briefly described above. Such alterations have been associated with abnormalities in various metabolic pathways [183]. Epigenetic control includes methylation of CpG rich regions, post-transcriptional modulation of chromatin histone/non-histone, and micro-RNAs (miRNAs) regulating gene expression [184–186]. Importantly, while these alterations may persist for cells lifespan and may have inter-generational effects, they are reversible and have thus become prime targets for interventions in the treatment of MetS [187]. Unfortunately, data on these mechanisms, particularly those bearing on DNA methylation and histone acetylation, are scarce. Table 3 shows that, in both animal models and human studies, polyphenol consumption decreases obesity, IR, and hypertension. These metabolic improvements are associated to epigenetic modifications, including increased DNA methylation, and histone methylation and acetylation.

Interestingly, reports involving miRNAs are more profuse. Table 4 summarizes the major findings obtained regarding the modulation of miRNAs and their effect on the expression of specific genes. It can be appreciated that polyphenols, independently of their origin, modulate miRNAs, especially controlling OxS and inflammation pathways in different cell models. In animal models, they also regulate miRNAs expression involved in the control of inflammation, obesity, lipogenesis, and energy expenditure. One human study shows that polyphenol consumption modulates miRNAs expression related to inflammation processes.
Table 3. Effect of polyphenols on DNA and histone methylation and acetylation.

| Polyphenols          | Experimental Model      | Tx Duration (Week) | Polyphenol Dosage | Epigenetic Modifications                | Outcomes in Response to Polyphenols                  | Ref |
|----------------------|------------------------|-------------------|-------------------|-----------------------------------------|------------------------------------------------------|-----|
| Raspberry extract    | HFD-fed mice           | 16                | 120 mg/kg/d       | ↑ AT Histone methylation and acetylation | ↓ Obesity ↓ IR ↓ Inflammation ↓ Liver steatosis        | [188] |
| Quercetin and Q2 derivative | HFD-fed rats           | 12                | 0.26 mg/kg/d      | ↑ AT Histone methylation                | ↓ Obesity ↓ IR ↓ Dyslipidemia ↓ Liver steatosis        | [189] |
| Apples               | HFHSD-fed rats         | 8                 | 700 mg/kg/d       | ↑ Methylation Aqp7 ↑ PGC genes ↑ Methylation leptin gene | ↓ Obesity ↑ AT lipolysis                              | [190] |
| Cocoa                | Humans Pre-hypertension or hypercholesterolemia | 2                 | 6 g/d             | ↓ Leuk DNA methylation ↓ DNA Mtases methylation | ND                                                   | [191] |
| Resveratrol          | Salt-sensitive hypertensive rats | 0–12              | 50 g/L drinking water | ↑ histone H3K27me3 in renal aorta | Prevention of hypertension ↑ Antioxidant defence | [192] |

Tx: treatment; HFD: high-fat diet; HFHSD: high-fat high-sucrose diet; miR: micro-RNA; IR: insulin resistance; AT: adipose tissue; Leuk: leukocytes; Mtases: methylases; ND: no data; ↑: increase; ↓: decrease.
### Table 4. Effects of polyphenols on the regulation of miRNAs on oxidative and inflammation pathways.

| Polyphenols                        | Experimental Model/Conditions                                      | Regulated miRNAs | Expression Pattern and Function                                                                 | Ref     |
|-----------------------------------|------------------------------------------------------------------|------------------|-------------------------------------------------------------------------------------------------|---------|
| **Cellular models**               |                                                                  |                  |                                                                                                |         |
| Quercetin and Isorhamnetin        | Pre LPS Tx stimulation of murine RAW 264.7 macrophages. Polyphenols (0, 10–100 µmol/L) | ↓miR-155         | ↓TNFα, ↓iNOS, ↓IL-1β, ↓IL-6, ↓MIP1α, ↓NF-kB ↑Nrf2 and ↑ARE                                      | [193]   |
| Resveratrol                       | Human THP-1 cell line HPBMC                                      | ↓miR-155         | ↓basal AP-1 and ↓LPS-induced AP-1 ↓JunB/D mRNA                                                 | [194]   |
| EGCG                              | IL-1β-stimulated human OA chondrocytes                          | ↑hsa-miR-199a-3p | ↓COX-2 mRNA/protein expression ↓PGE₂ production                                                 | [195]   |
| EVOO oleocanthal (OC) and oleacein (OA) secoiridoids | SGBS adipocytes pretreated with OC or OA before stimulation by TNFα | ↓miR-155-5p, ↓miR-34a-5p ↑let-7c-5p | ↓IL-1β, ↓COX-2, ↓MMP-2, ↓NF-kB, ↓NADPH oxidase ↑SOD and ↑GPx ↑PPARy ↑MCP-1, ↑CXCL-10, ↑M-CSF | [196]   |
| Olive oil hydroxytyrosol (HT)     | SGBS adipocytes pretreated with HT before stimulation by TNFα    | ↓miR-155-5p, ↓miR-34a-5p ↑let-7c-5p | ↓MCP-1, ↓CXCL-10, ↓IL-1β, ↓IL-6, ↓VEGF, ↓COX-2, ↓M-CSF, ↓MMP-2, ↓NF-B and ↓ROS production ↑GPX ↑eNOS ↑PGC-1α | [197]   |
| Propolis extracts                 | HaCat cell line treated for 24 h with propolis extracts (3.125, 1.56, and 0.78 mg/mL) | ↑miR-19a-3p ↑miR-203a-3p ↑miR-27a-3p ↓miR-17-3p | ↓TNFα mRNA ↓NFE2L2 mRNA ↑GPX2 ↑MnSOD and ↑TRXR2 mRNAs                                      | [198]   |
| Curcumin polyphenolic compound    | ARPE-19 cells treated with 20 µM curcumin and 200 µM H₂O₂       | ↑miR-146a↑miR-155 ↓miR-23b ↓miR-27b ↓miR-26b ↓miR-15b ↓miR-9 ↓miR-30b, miR-30e | ↓NF-κB ↑CAT, ↑GPx                                                                          | [199]   |
### Table 4. Cont.

| Polyphenols                                      | Experimental Model/Conditions                  | Regulated miRNAs | Expression Pattern and Function | Ref |
|--------------------------------------------------|------------------------------------------------|------------------|---------------------------------|-----|
| Açai and red muscadine grape polyphenols         | HUVEC ROS induction by 25 mM glucose for 30 min | ↑miR-126, ↑MiR146a | ↑IL-6, ↓IL-8, ↓NF-kB, ↓PXR, ↓VCAM-1, ↑CYP1A1, ↑MDRP1, ↑CAT, ↑GST activity | [200] |
| Resveratrol                                      | LPS-stimulated THP-1 macrophages pretreated with resveratrol | ↑miR-Let7A       | ↓TNFa, ↓IL-6, ↓IL-10, ↓IL-4, ↓SIRT1 mRNAs | [201] |
| Animal models                                    |                                                |                  |                                 |     |
| Quercetin                                        | Ctrl or HFD C57BL/6 J fed mice 0.2 or 2.0 mg/g diet | ↑miR-125b        | ↓IL-6, ↓CRP, ↓MCP-1, ↓AOAH, ↓HO-1, ↓Ref-1, ↓TLR-2 mRNAs | [202] |
| Grape seed extract                               | HFD-fed obese Rats 30 mg/kg/d                  | ↓miR-33a, ↓miR-122 | ↓TC, ↓TAG, ↓LDL-C, ↓TNFa, ↓liver MDA ↑SOD, CAT, ↑liver GSH | [203] |
| Polydatin (3,4’,5-trihydroxy-stilbene-3-β-D-glucoside) | Ctrl, or HFrD, HFrD + Polydatin (7.5, 15, 30 mg/kg), HFrD + PG (4 mg/kg) fed SD rats IG saline, polydatin or PG 7 week | ↓ miR200-a       | ↓ TXNIP, ↓NLRP3, ↓ASC, ↓Casp-1, ↓SREBP-1 and ↓SCD-1 ↑ PPAR-α and ↑CPT-1 | [204] |
| Tea extract                                      | HFD-fed mice for 12 weeks 500 mg/kg/d          | ↓miR-335, ↓miR-155 in AT | ↓Obesity, ↓IR, ↓Inflammation, ↑Energy expenditure | [205] |
| Resveratrol                                      | HFHS-fed rats for 6 weeks 30 mg/kg/d            | ↑miR-211-3p, ↑miR-1224, ↑miR-539-5p, ↓AT miR-511-3p | ↓Obesity, ↓AT lipogenesis | [206] |
Table 4. Cont.

| Polyphenols | Experimental Model/Conditions | Regulated miRNAs | Expression Pattern and Function | Ref |
|-------------|-------------------------------|------------------|---------------------------------|-----|
| Resveratrol | T2D HT patients. 1-year daily intake of grape extract (8.1 mg/d for first 6 months and 16.2 mg/d for last 6 months) | HPBMC ↑miR-21 ↑miR-181b ↑miR-663 ↑miR-30c2 | ↓IL-6, CCL-3, IL-1β, TNFα, ↑LRRFIP-1 | [207] |

Tx: Treatment; Ctrl: control, HFD: high-fat diet; HFrD: high-fructose diet; PG: pioglitazone; SD: Sprague-Dawley rat; ARPE-19 cells: adult retinal pigment epithelial cell line-19; HUVEC: human umbilical vascular endothelial cells; THP-1: human monocyte leukemia cells; LPS: lipopolysaccharides; TNFα: tumor necrosis factor alpha; iNOS: inducible nitric oxide synthase; IL-1β: interleukin-1β; IL-6: interleukin-6; MIP-1α: macrophage inflammatory protein-1α; NF-κB: nuclear factor κB; Nrf2: NF-E2-related factor 2; AOAH: acyloxyacyl hydrolase; HO-1: heme oxygenase-1; Ref-1: redox factor-1; TLR-2: toll like receptor-2; ARE: antioxidant response element; CRP: C-reactive protein; MCP-1: monocyte chemo-attractant protein-1; T2D: type-2 diabetes; HT: hypertensive; HPBMCs: human peripheral blood mononuclear cells; LRRFIP-1: leucine-rich repeat flightless-interacting protein-1; HaCat: human keratinocyte cell line; IA: intra-arterial; ASC: apoptosis-associated Speck-like protein Casp1; caspase-1; SG: Simpson–Golabi–Behmel syndrome; ALP: alkaline phosphatase; CCL-3: chemokine (C-C motif) ligand-3; TC: total cholesterol; TAG: triacylglycerol; LDL-C: low-density lipoprotein cholesterol; TAC: total antioxidant capacity; MDA: malondialdehyde; SOD: superoxide dismutase; CAT: catalase; GPX: glutathione peroxidase; GSH: glutathione, OA: osteoarthritis; COX2: cyclooxygenase-2; PGE2: prostaglandin-E2; EGCG: epigallocatechin-3-O-gallate; MMP-2: matrix-degrading enzyme metalloproteinase; NADPH oxidase: nicotinamide adenine dinucleotide phosphate oxidase; CXCL-10: C-X-C motif ligand 10; M-CSF: macrophage colony-stimulating factor; PARP: peroxisome proliferator-activated receptor; NFE2L2: nuclear factor, erythroid 2 like 2; TRXR2: thioredoxin reductase 2; MnSOD: manganese superoxide dismutase; TXNIP: thioredoxin-interacting protein; NLRP3: NOD-like receptor (NLR) family; PPARα: peroxisome proliferator activated receptor-α; CPT1: carnitine palmitoyl transferase-1; SREBP-1: sterol regulatory element binging protein 1; SCD-1: stearoyl-CoA desaturase-1; vEGF: vascular endothelial growth factor; eNOS: endothelial nitric oxide synthase; PGC-1α: peroxisome proliferator-activated receptor coactivator 1α; GLUT4: glucose transporter-4; VCAM-1: endothelial vascular cell adhesion molecule-1; PXR: pregnane X receptor; GST: glutathione S-transferase; MDRP1: multidrug-resistant protein 1, CYP1A1: cytochrome P450; SIRT1: sirtuin 1; ↑: increase; ↓: decrease.
5. Polyphenol Metabolites

In the first part of the present review, we have defined the polyphenols, described their structure, reported their digestion and absorption, elaborated on their mode of action and potential benefits, emphasized their epigenetic regulation, and pointed out their interaction with intestinal microbiota. The goal of the second part is to focus on the polyphenol metabolites, derived from their colonic microbial metabolism and biotransformation. As mentioned above, parent or native polyphenols have glycosidic linkages, which limit their absorption in the small intestine, forcing them to continue their way to the colon. It is in this part of the large intestine that glycosides are cleaved and further metabolized by microbiota to potentially generate more active and better-absorbed metabolites. Using transporters and passive diffusion, the small molecular weight end-products have easy access to the circulation. Hence, the second part of this review is dedicated to specify the biological activity and consequential functional effects of polyphenol metabolites on CMD. Table 5 provides information on the different metabolites issued from colonic digestion and on their pleiotropic effects.

5.1. Flavonoid Metabolites and Their Antioxidant and Anti-Inflammatory Effects

Bacterial flavonoid catabolism in the colon follows a generic pattern yielding non-specific metabolites such as hydroxylated phenylpropionic acid (HPPA) and phenylacetic acids (HPAA) that ultimately may be subjected to β-oxidation and glycination to yield hippuric acid and its hydroxylated counterpart [34,217]. It can therefore be appreciated that a relatively small number of degradation products emanate from extremely diverse parent flavonoids.

5.1.1. Flavonol Quercetin Metabolites

Quercetin (2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one) is supplied by apples, tea, red wine, berries, tomatoes, and onions. This polyphenol has attracted a lot of interest from the biomedical milieu in view of its beneficial properties in prevention-diseases (e.g., T2D, CVD) despite its limited bioavailability because of its low solubility, weak stability in the upper gastrointestinal tract, rapid fast metabolism, and short biological half-life [98]. However, quercetin molecules unable to be absorbed in the small intestine reach the colon, and are metabolized into a series of phenolic acids by luminal bacteria [265]. In fact, the health-promoting properties observed with quercetin could account for by microbiota-mediated metabolites.

Quercetin, quercetin 3-O-rutinoside (rutin) and their colon-derived flavonoid metabolites 3,4-dihydroxyphenylacetic acid (3,4-HPAA), 4-hydroxyphenylacetic acid (4-HPAA), 3-hydroxyphenylacetic acid (3-HPAA), and hippuric acid (N-benzoylglycine) have been shown to possess antioxidant and anti-inflammatory properties. On the other hand, when in vitro studies using primary cultures of rat liver parenchymal cells or the human HepG2 hepatoma cell line were treated with t-butylhydroperoxide to produce OxS, the radical scavenging properties were noted only for the parent molecules quercetin and rutin, as well as for 3,4-dihydroxytoluene (3,4-DHT). The metabolites 3-HPAA, 4-HPAA, and hippuric acid remained almost ineffective [208]. Similarly, quercetin and 3,4-DHT showed the potency to inhibit cholesterol synthesis. Another in vitro study, testing the radical scavenging capacity of 3,4-DHPAA, 3-HPAA, and 4-HPPA in human polymorphonuclear cells (stimulated with opsonized zymosan or N-formyl-methionyl-leucyl phenylalanine) revealed that out of the 3 metabolites investigated, only 3,4-DHPAA was active [209]. This radical scavenging capacity is of utmost importance when considering the cell protection from cytotoxicity. Indeed as an adjunct to its radical scavenging properties, 3,4-DHPAA activates phase 2 cytoprotective enzymes (i.e., hemoxynegese-1, glutathione S-transferase), increases the gene and protein expression of aldehyde dehydrogenase isozymes in mouse hepatoma Hepa1c1c7 cells, and induces nuclear translocation of Nrf2 and aryl hydrocarbon receptor [210,211], all involved in controlling cellular REDOX status and in inhibiting cell cytotoxicity.
Table 5. Polyphenol metabolites and functions.

| Polyphenols | Subclasses | Metabolites | Bacterial Catabolism | Metabolites Functions | Ref |
|-------------|------------|-------------|----------------------|-----------------------|-----|
| **Flavonols** |            |             |                      | Oxygen radical scavenging (all the metabolites), SOD-like activities (3,4 DHPAA), ↑glutathione S-transferase (3,4 DHPAA), ↑Nrf2-AhR (3,4 DHPAA) | [132,208–220] |
|             |            | Quercetin   | Clostridium orbiscidens | ↑Glucose induced-insulin secretion (3,4 DHPAA) | [132,208,209,212–215,221] |
|             |            |             | Eubacterium oxidoreducens | ↑Function and survival of pancreatic β-cells (3,4 DHPAA) | [132,208,209,212–215,221] |
|             |            |             | Eubacterium ramulus | Protective effect against OxS induced-endothelial dysfunction (3,4 DHPAA) | [132,208–220] |
|             |            |             | Enterococcus casseliflavus | | |
|             |            | 3,4-DHPAA   |                       |                       | |
|             |            | 3-HPAA      |                       |                       | |
|             |            | 4-HPAA      |                       |                       | |
| **Flavones** |            |             |                      | ↓Oxygen radical scavenging (3-HPPA) | [132,208] |
|             |            | Apigenin    | Clostridium orbiscindens | ↑Glucose induced-insulin secretion (3-HPPA) | [132,208,209,212–215,221] |
|             |            |             |                       | ↑Function and survival of pancreatic β-cells (3-HPPA) | [132,208,209,212–215,221] |
|             |            | 3-HPPA      |                       |                       | |
|             |            | 4-HPPA      |                       |                       | |
|             |            | 4-HCA       |                       |                       | |
Table 5. Cont.

| Polyphenols | Subclasses | Metabolites | Bacterial Catabolism | Metabolites Functions | Ref |
|-------------|------------|-------------|----------------------|-----------------------|-----|
| **Flavanones** | Naringenin | 3,4-DHPPA | Clostridium strains | ↓Oxygen radical scavenging (3-HPPA) | [34,60,209,212–215,217,222,223] |
|             |            | 3-HPPA     | Eubacterium ramulus | ↓Proinflammatory; 3,4 DHPPA) |     |
|             |            | 4-HPPA     |                      | ↑Glucose induced-insulin secretion (3-HPPA) |     |
| **Isoflavones** | Daidzein (S)-Equol | O-DMA | Bacteroides ovatus, Streptococcus intermedius, Ruminococcus productus, Eggerthella sp.Julong 732, Enterococcus faecium EPI1, Lactobacillus mucosae EPI2, Finegoldia magna EPI3, Clostridium spp. HGHA136 | Stimulation of cellular antioxidant systems | [224–226] |
|             |            |            |                      | ↑Catalase and SOD activity |     |
|             |            |            |                      | Anti-atherogenic effect |     |
Table 5. Cont.

| Polyphenols | Subclasses | Metabolites | Bacterial Catabolism | Metabolites Functions | Ref |
|-------------|------------|-------------|----------------------|-----------------------|-----|
| Flavan-3-ols | Monomers (catechins, epicatechins) and proanthocyanidins | 3-HPPA, 3,4-DHPPA, 3',4' DHPVL, 3'-HPVL, 3',4',5'-THPVL, 3',5'-DHPVL | Clostridium coccoides, Bifidobacterium spp. Eggerthella lenta Flavonifractor plautii | ↓Oxygen radical scavenging (3-HPPA) ↓ROS generation (3'-HPVL, 3',4'-DHPVL) ↓NF-κB transcriptional activity ↓NO synthesis (3',4',5'-THPVL; 3',4'-DHPVL) ↓iNOS expression (3',4'-DHPVL) Maintenance of endothelial homeostasis and functions (3',4'-DHPVL); ↓Endothelial adhesion (3',4'-DHPVL) ↓VCAM1 and MCP1 (3',4'-DHPVL) ↓Systolic blood pressure (3',4',5'-THPVL; 3',5'-DHPVL) | [87,92,109,131,227–236] |
| Anthocyanins | Cyanidin, Peonidin, Pelargonidin, Malvidin, Delphinidin | Protocatechuc acid, Vanillic acid, 4-Hydroxybenzoic acid, Syringic acid, Gallic acid | Lactobacillus plantarum, Lactobacillus casei acidophilus LA-5, Bifidobacterium lactis BB-12 | Antidiabetic activities due to their antioxidant capacity ↓DNA damages, ↓ROS production ↑Cellular glutathione level, ↑glucose uptake by HepG2 and human skeletal cells, ↑glycogen production by HepG2 cells, ↑Mitochondria homeostasis | [237–242] |
| Polyphenols               | Subclasses | Metabolites       | Bacterial Catabolism | Metabolites Functions                                                                 | Ref                      |
|--------------------------|------------|-------------------|----------------------|---------------------------------------------------------------------------------------|--------------------------|
| Hydroxycinnamic acids    | Chlorogenic acids | 3-HPPA, 3,4-DHPPA, Caffeic acid | Escherichia coli, Bifidobacterium lactis, Lactobacillus gasseri | ↓Oxygen radical scavenging (3-HPPA)  
↓Proinflammatory cytokines (3-HPPA; 3,4 DHPPA)  
Antidiabetic activities due to its antioxidant capacity (caffeic acid):  
↑Cellular glutathione level  
↓DNA damages  
↓Cytotoxicity, ↓ROS production  
↑Glucose consumption  
↑Glycogen production | [209,212,214,215,243,244] |
| Hydrolyzables tannins    | Ellagic acid, Urolithin A, Urolithin B | Butyrivibrio spp. | | ↓Intracellular ROS accumulation (Urolithin A)  
↓Cellular injury by ROS  
↓Proinflammatory mediators (Ellagic acid and Urolithin A)  
↓NADPH oxidase activation (Urolithin A)  
↓PGE2 production (Urolithin A and B)  
↓mPGES-1 and COX-2 expression (Urolithin A and B)  
↓Proteins glycation (Urolithin A and B)  
↓Triglycerides accumulation (Ellagic acid and Urolithin A)  
↓Expression of adipogenic protein and gene (Urolithin A)  
↑Fatty acid β-oxidation (Urolithin A)  
Alleviation of myocardial ischemia/reperfusion injury (Urolithin A) | [245–257] |
Table 5. Cont.

| Polyphenols | Subclasses | Metabolites | Bacterial Catabolism | Metabolites Functions | Ref |
|-------------|------------|-------------|----------------------|-----------------------|-----|
| Lignans     |            |              | Bacteroides distasonis, Bacteroides fragilis, Bacteroides ovatus, Clostridium cocleatum, Butyribacterium methylotrophicum, Eubacterium callenderi, Eubacterium limosum, Peptostreptococcus productus, Clostridium scindens, Eggerthella lenta | Antioxidant capacity OH-scavenging activity Immunomodulatory effects in human cells ↓NF-κB transcriptional activity ↓Proinflammatory cytokines expression | [258–261] |
| Secoisolariciresinol | Enterodiol Enterolactone |            |                      |                       |     |
| Stilbenes   |            | Trans-resveratrol | 3,4′-dihydroxy-trans-stilbene 3,4′-dihydroxybibenzyl (lunularin) | Slackia equiliifaciens Adlercreuzia equiliifaciens | Antioxidant activity Free radical scavenging (DHR) ↓NO production (DHR) | [262–264] |

3,4-DHPPA, 3,4-dihydroxyphenylpropionic acid; 3-HPPA, 3-hydroxyphenylpropionic acid; 4-HPPA, 4-hydroxyphenylpropionic acid; 4-HCA, 4-hydroxycinnamic acid; 3,4-DHPAA, 3,4-dihydroxyphenylacetic acid; 3-HPAA, hydroxyphenylacetic acid; 4-HPAA, 4-hydroxyphenylacetic acid. O-DMA, O-demethylangolensin, 3,4-DHPPA, 3,4-dihydroxyphenyl-γ-valerolactone; 3′,4′-DHPVL, 3′,4′-dihydroxyphenyl-γ-valerolactone; 3′,5′-DHPVL, 3′,5′-dihydroxyphenyl-γ-valerolactone 3′,HPVL, 3′-hydroxyphenyl-γ-valerolactone; DHR, dihydroresveratrol, NO: nitric oxide; ↑: increase; ↓: decrease.
In vitro studies have also established the anti-inflammatory properties of quercetin metabolites. For example, experiments with lipopolysaccharide-stimulated human peripheral blood mononuclear cells showed the modulatory effect of 3,4-DHPPA, 3-HPPA, 3,4-DHPAA, 3-HPAA, and 4-hydroxybenzoic acid on the expression of the central pro-inflammatory cytokines; TNFα, IL-1β, and IL-6. TNFα expression was also significantly decreased by the metabolites 3,4-DHPPA, 3,4-DHPAA, and 4-hydroxy-hippuric acid (4-HHA), whereas 3,4-DHPPA and 3,4-DHPAA only suppressed secretion of IL-1β and IL-6 [212]. In another study, in which lipopolysaccharide was used to induce inflammation in RAW 264.7 murine macrophage cell line, 3,4-DHT disclosed an anti-inflammatory capacity by modulating the IκB/NF-κB signaling pathway [266].

Surprisingly, very little research has highlighted the potential anti-diabetic properties of colonic metabolites derived flavonoids. However, when the ability of DHPAA and HPPA was examined on β cell function, the findings clearly emphasized an elevated glucose-stimulated insulin secretion, high protection against tert-butyl hydroperoxide-induced β cell toxicity, hence better survival and function of β cells [215]. The last functions were mediated by the activation of protein kinase C and the extracellular regulated kinases (ERKs) pathways. Collectively, these interesting data suggest that flavonol quercetin/rutin metabolites exert anti-diabetic actions.

5.1.2. Flavones and Flavanones Metabolites

Flavones (e.g., apigenin) are present in foods as cereals, parsley, thyme, celery, and citrus fruits under their O-glycosidic or C-glycosides derivatives. Once glucosides are hydrolyzed at the intestinal level by digestive enzymes, unabsorbed aglycons undergo further reactions in the large intestine by specific micro-organisms (Clostridium orbiscindens, Enterococcus avium) causing C-ring fission. Following the metabolism of apigenin, metabolites [e.g., phloretin chalcon, 3-(4-hydroxyphenyl)-propionic, 3-(3-hydroxyphenyl)-propionic, and 4-hydroxycinamic acids] are acquired [221].

Flavanones (e.g., naringenin) are abundant in tomatoes and citrus fruits, and seem to have higher bioavailability in comparison to flavonols and flavan-3-ols [267]. Flavanone deglycosylation and further degradation by colonic microbiota pathways follow the similar fate of flavonols [267]. Clostridium species and Eubacterium ramulus are largely involved in these transformations in the colon [217,268]. Metabolites, including 3-(3,4-dihydroxyphenyl)-propionic, 3-(4-hydroxyphenyl)-propionic, and 3-(3-hydroxyphenyl)-propionic acids are produced following naringenin metabolism. However, as for quercetin metabolites, hydroxyphenyl propionic acids (derived from apigenin and naringenin metabolism) display antioxidant and anti-inflammatory capacities (Table 5).

5.1.3. Isoflavone Daidzein and Daidzin Metabolites

Isoflavone, as a phytoestrogen precursor, is another flavonoid class of interest. Like many types of polyphenols, isoflavones exert advantageous effects on intestinal health, menopause symptoms, hormone-mediated syndromes, and CVD [269]. They are also transformed into their active metabolites by enzymes from the gut microbiota to generate compounds endowed with elevated estrogenic activity (e.g., 4′,7-isoflavandiol; equol) or inactive compounds (e.g., O-desmethylandolensin; O-DMA) [270]. Importantly, the majority of humans are competent to yield O-DMA, but only 25–50% among them engender equol [271,272].

The potential health properties of equol and O-DMA, both derived from daidzein and its 7-O-glycoside daidzin, are the subject of continuing debate. Some studies claim their beneficial effects on the risk of coronary heart disease events [273,274] and others have shown a limited action [275]. The diverging conclusions stems in part from the inter-individual variability in the gut microbiota [276] or from a characteristic that is influenced by ethnicity [277]. Interestingly enough, prehypertensive postmenopausal women producing equol/O-DMA had more favorable cardiovascular risk profiles than non-producers [278]. Furthermore, equol/O-DMA producers exhibited lower serum uric acid, triglycerides, and waist/hip ratio, as well as a tendency to have higher high
density lipoprotein-cholesterol compared to equol non-producers [279]. These effects are probably exerted through the control of cell redox potential as both equol and O-DMA have antioxidant capacity, exemplified by the stimulation of catalase and total superoxide dismutase activities [226]. In a population-based, cross-sectional investigation, urinary concentrations of isoflavones and equol/O-DMA were related to well-disposed insulin sensitivity and cardiometabolic markers in pregnant women [280]. Other studies emphasized the beneficial role of O-DMA in obesity [281]. However, caution should be exerted when concluding on the effects of isoflavone and related metabolite interventions, as sufficiently randomized controlled trials with statistical are needed [275].

5.1.4. Flavanol Catechin Metabolites

Flavanols or flavan-3-ols are among the most consumed phenolic compounds in Western populations [282]. They are composed of monomers (e.g., catechin, epicatechin, epigallocatechin) and oligomers/polymers (known as proanthocyanidins) [283]. Several groups have reported their ability to prevent chronic diseases (e.g., T2D and CVD) [283–285]. Hydroxy-phenyl-γ-valerolactones and their related hydroxy-phenylvaleric acids are the main metabolites of dietary flavan-3-ols [87,286]. Although a number of studies based on different models aiming at assessing hydroxy-phenyl-γ-valerolactones bioactivity have been reported in the past decade, those involving human subjects are scarce. Inflammatory and OxS processes were particularly studied. For example, (3′,4′-dihydroxyphenyl)-γ-valerolactone significantly decreased TNFα-induced NF-kB transcriptional activity in HepG2 cells [92]. Furthermore, a decrease was noted in nitrous oxide production and inducible nitrous oxide synthase expression in the murine macrophage RAW264.7 cells and freshly isolated human monocytes, both treated with (δ-(3,4-dihydroxyphenyl)-γ-valerolactone) a metabolite of the maritime pine bark Pycnogenol [233].

The accumulation of pro-inflammatory cytokine-producing T-lymphocytes and macrophages with the concomitant secretion of the vascular cell-adhesion molecule-1 by the endothelium is key to the early development of the atherosclerotic plaque [287]. Inhibition of this process was observed following the incubation of cultured human umbilical vein endothelial cells with 3′,4′-dihydroxyphenyl-γ-valerolactone [234], thereby providing the evidence that this compound is a potential therapeutic target. Transferability of the concentrations (quantities) of natural compounds to in vivo or clinical environment (cytotoxicity) represents a major limit of these in vitro experiments. The polyphenolic metabolites 3′,4′,5′-trihydroxyphenyl)-γ-valerolactone and 5-(3′,5′-dihydroxyphenyl)-γ-valerolactone also displayed, in spontaneously hypertensive rats, the capacity to lower angiotensin-1 converting enzyme activity and blood pressure, both contributing to improving endothelial function and arterial elasticity [235]. Paradoxically, the flavan-3-ol metabolites 5-(3′,4′,5′-trihydroxyphenyl)-γ-valerolactone, 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone, and 5-(3′-methoxy, 4′-hydroxyphenyl)-γ-valerolactone did not improve vascular endothelial plasticity of freshly isolated mouse saphenous arteries [236]. The dissimilarity in data could partially be explained by the different models used, especially that isolated saphenous artery endothelium is less reactive than the vessels of the spontaneously hypertensive rat. The in vivo versus the in vitro situations and the experimental time frame are also factors that have to be considered.

The decrease in obesity, a major element in the development of MetS, in response to the consumption of foods rich in flavan-3-ols (e.g., green tea), has been attributed to the role of their content on polyphenolic metabolites in increasing energy expenditure via the modulation of cell differentiation and thermogenesis in adipose tissues [231]. However, when tested in vitro, the flavan-3-ol metabolites [5-(3′,4′-dihydroxyphenyl)-γ-valerolactone, 5-(3′-hydroxyphenyl)-γ-valerolactone-4′-O-sulfate, and 5-phenyl-γ-valerolactone-3′,4′-di-O-sulfate] did not stimulate cell differentiation and the activation of immortalized pre-adipocytes. In addition, none of the metabolites regulated the expression of the uncoupling protein 1, nor the main transcription factors implicated in brown adipocyte genesis. Nevertheless, both 5-(3′,4′-dihydroxyphenyl)-γ-valerolactone and 5-(3′-hydroxyphenyl)-γ-valerolactone-4′-O-sulfate protected immortalized pre-adipocytes from
H$_2$O$_2$ generated OxS [231]. In a recent clinical trial, Rodriguez-Mateos et al. [288] showed that cranberry juice given to healthy volunteers improved, in a concentration- and time-dependent manner, the flow-mediated vasodilatation, an early clinical sign in the development of atherosclerosis. Interestingly, the plasma level of the flavan-3-ols metabolite, 5-(3'-hydroxyphenyl)-γ-valerolactone-4'-sulfate, was significantly positively correlated to flow-mediated vasodilatation. Noteworthy, mice on high-fat diet improved non-alcoholic fatty liver disease by lessening IR and endotoxin-toll-like receptor 4/NF-κB pathway in response to raised hepatic catechin metabolites (namely phenyl-γ-valerolactones) following catechin-rich green tea extract [289].

Overall, these findings offer promising beneficial health effects of polyphenols metabolites. However, additional clinical studies are necessary to validate the data in humans and to ensure their transferability from in vitro and animal models to in vivo human situations.

5.1.5. Tannin Ellagitannin and Urolithin Metabolites

Hydrolysable tannins, named ellagitannins, encompass one or more gallic acid units and one or more hexahydroxydiphenolic acid units, ester-connected with a sugar residue. In view of their difficulty to be absorbed in the small intestine, ellagitannins reach the colon where they are hydrolyzed into mainly ellagic acid and urolithin (3,4-benzocoumarin derivatives). Supporting data propose a stringent relationship between the consumption of ellagitannins-rich foods and healthy effects based on animal and human models.

The rat under high carbohydrate high-fat diet-induced MetS model has demonstrated the ability of ellagic acid to improve hepatic and cardiometabolic functions, while normalizing glucose tolerance, blood lipid components, central obesity, and body weight [290]. The mechanisms involved in the modulation of OxS and inflammation are through the protein level regulation of Nrf2 and NF-κB, with an impact on metabolic pathways such as fatty acid β-oxidation [290]. Other studies confirm the health benefit properties of ellagic acid, for example, by showing that it dose-dependently repressed the IL-1β-induced production of ROS [248]. This was associated with a significant reduction of the attachment of the established human monocyte cell line to IL-1β-treated human umbilical vein endothelial cells through the suppression of NF-κB, thereby downregulating the expression of vascular cell-adhesion molecule-1 and E-selectin and resulting in decreased monocyte adhesion. Along the same line of evidence, ellagic acid significantly inhibited oxidized low-density lipoprotein and platelet-derived growth factor-BB-induced proliferation of rat aortic smooth muscle cells via inactivation of ERK and marked decrease of proliferating cell nuclear antigen. [249]. More evidence for ellagic acid effects in preventing the development of atherosclerotic events has been provided by showing its capacity of reducing platelet growth factor (PDGF) receptor-β-phosphorylation, diminishing ROS production, and lessening downstream activation of ERK, and finally blocking platelet-derived growth factor-induced expression of cyclin D1 in primary cultures of rat aortic smooth muscle cells [291]. Moreover, these in vitro results were further supported by the ability of ellagic acid to block T2D-induced medial thickness, and lipid and collagen deposition in the arch of aorta in streptozotocin-induced diabetic rats [291]. Collectively, these data suggest that ellagic acid can inhibit OxS and inflammation response, which thus favorably contributes to the regulation of vascular homeostasis.

Urolithins, formed primarily from the oxidative linkage of galloyl groups, have extensively emerged as novel natural bioactive compounds, being currently the focus of extensive investigations. The type of urolithin produced depends on the colon microbiome. Three ellagitannins-metabolizing metabolotypes have been identified: ‘metabotype A’ (producers of the dihydroxylated urolithin-A conjugates), ‘metabotype B’ (producers of urolithin-A/iso- urolithin-A conjugates and/or monohydroxylated urolithin-B conjugates), and ‘metabotype 0’ (no urolithins produced) [292]. Contrary to the parent compounds, which bloodstream concentrations are negligible, these ellagic acid derivatives may reach micromolar concentrations and thus act as surrogate biomarkers of the inter-individual variation in the colon metabotype [245]. Among the numerous metabolites, urolithin-A
has been particularly studied in terms of its anti-inflammatory and anti-oxidative properties both in vitro and in vivo [250,293,294], as well as anti-atherosclerotic and anti-angiogenic activities [293,295]. In line with these features, adhesion model involving established human aortic endothelial cells and human leukemia monocytic THP-1 cells showed that urolithin-A inhibited TNFα-stimulated adhesiveness and endothelial cell migration [257]. To delve deeper and uncover the mechanisms, the authors could further demonstrate that these effects were concomitant to a down regulation of the levels of chemokine ligand 2, plasminogen activator inhibitor-1, and IL-8. Even more interesting, a clinical trial provided evidence that overweight-obese individuals consuming ellagitannin-containing food with the urolithin metabotype producing urolithin-A were protected against CMD when compared to those with a urolithin-B metabotype [296]. Despite the small number of participants, this clinical trial pointed out the important inter-individual disparity in metabolizing polyphenols, the regulation by microbiota, and indicated that urine metabolite profiling is a valuable tool in assessing potential effects. Fecal polyphenol metabolite profiling could also shed some light on the mechanisms of action. In this context, the profile of fecal phenolic-derived metabolites correlated to blood biomarkers of OxS and inflammation, thus providing support to this avenue [297].

Urolithin may constitute a central regulator of CMD as IR decreased in response to urolithin administration to mice fed high-fat, high-sucrose diet [298]. Concomitantly, urolithin lowered glucose, fatty acids, and triglycerides, while ameliorating adiponectin and mitochondrial function. Furthermore, in the same animal model, through thyroid hormone modulation, urolithin increased energy expenditure by enhancing thermogenesis in brown adipose tissue and inducing browning of white adipose tissue [299]. Therefore, this first-in-class natural compound contributed to metabolic homeostasis via its capacity to normalize OxS, inflammation, obesity, and IR, which overall contribute to MetS.

5.2. Non-Flavonoids

5.2.1. Lignan Metabolites

Plant lignans are non-flavonoids, but polyphenolic, phytoestrogenic compounds. They exhibit several biological functions with potent protective benefits. Anti-estrogenic, antioxidant, anti-inflammatory, anti-atherosclerotic, and anti-carcinogenic effects are among their properties, thereby conferring therapeutic values [300,301]. These properties explain the impact of lignan-rich diets on the prevention of hyperlipidemia, IR and hyperglycemia, T2D, and CMD [302–304]. The most frequent forms of dietary lignans are secoisolariciresinol, lariciresinol, pinoresinol, and matairesinol, which are metabolized by gut microflora enzymes into enterolignans such as enterodiol and enterolactone undergoing enterohepatic circulation [305,306]. At least, 28 bacterial species belonging to 12 different genera (e.g., Bacteroides, Clostridium, Bifidobacterium, and Ruminococcus) have been identified to be involved in the transformation of lignans to enterolignans [307]. Several groups have quantified the concentrations of the enterolactone metabolite in blood and urine, and reported a protective association in view of the reduction (30–45%) of cardiovascular mortality [308]. Similarly, in a prospective investigation, enterolactone (more than enterodiol) was associated with a lower risk of T2D in U.S. women [309]. A cross sectional trial of the general U.S. population found that subjects with high excretion of enteractone had lower odds of having MetS [310]. Moreover, in a representative sample of U.S. adults, the cross-sectional analysis of data detected that urinary enterolignan concentrations are associated with lower serum triglyceride and greater high-density lipoprotein-cholesterol concentrations in U.S. adults [311]. Additional efforts are obviously needed to confirm these interesting cardiometabolic findings and to explore potential mechanisms of action behind diverse enterolignan metabolites.

5.2.2. Resveratrol Metabolites

Resveratrol (3,5,4′-trihydroxystilbene) belongs to the stilbene derivative and is a dietary polyphenolic compound accessible in 70 plant species such as grapes, mulberries, and peanuts [312].
Its pleiotropic effects have made it so famous that it is called a star molecule. It displays numerous biological activities, including antioxidant, anti-inflammatory, cardioprotective, anti-aging, and cancer-chemopreventive features [313,314]. Accordingly, the wealth of scientific reports revealed the effectiveness and beneficial actions of resveratrol in MetS and related disorders such as obesity, IR, and T2D [315,316]). For example, a meta-analysis evaluating 11 studies involving 388 T2D subjects mentioned that resveratrol markedly lessened fasting glucose, insulin, haemoglobin A1c, and IR [278]. Resveratrol was also able to improve hypertension by acting on vascular nitric oxide production, reducing endothelial dysfunction and arteriolar remodeling [317,318]. However, other studies could not record advantageous data on MetS in response to resveratrol [319].

Today, it is well established that resveratrol is easily absorbed by the intestine and promptly metabolized to produce glucuronide and sulfate conjugates [320,321]. Although many gaps are still persistent in the metabolic route of resveratrol, intestinal bacteria transform resveratrol into dihydroresveratrol, known to be partially absorbed and subsequently metabolized to conjugated forms, which can be excreted in urine [322,323]. Besides dihydroresveratrol, two additional bacterial trans-resveratrol metabolites were identified: 3,4′-dihydroxy-trans-stilbene and 3,4′-dihydroxybibenzyl (lunularin) [264]. Large inter-individual variation was noticed in different subjects: some of them were lunularin producers, others were dihydroresveratrol producers, and the last category was mixed producers, according to levels of these metabolites [264]. Clearly, there was a close relationship between lunularin producers and the abundance of Bacteroidetes, Actinobacteria, Verrucomicrobia, and Cyanobacteria, along with lower abundance of Firmicutes compared to dihydroresveratrol or mixed producers [264]. Whether resveratrol metabolites are physiologically relevant to tackle metabolic disorders still remains an enigma.

6. Conclusions

Consuming a diet rich in fruits and vegetables is associated with a reduced risk of several noncommunicable lifestyle-related diseases, including CVD. They contribute several essential and bioactive micronutrients such as polyphenols. The first goal of this review was to focus on the available and pertinent literature, which assessed the health-promoting potential of polyphenols to modulate OxS and inflammation. These two major components are powerful inducers of IR, leading to CMD, especially MetS and related complications such as T2D and atherosclerosis.

For the reader’s benefit, our review first summarized the most widely distributed classes, sources, and properties of the naturally occurring polyphenols, separated into two main groups, flavonoids and non-flavonoid compounds. Second, attention was paid to their transformation in the intestinal lumen, absorption in different regions of the GI tract, and their bioavailability in the bloodstream. Clearly, most of polyphenols undergo complex intraluminal transformation during digestive and absorptive processes. Data obtained from critical literature revision underline the poor bioavailability, aqueous solubility, permeability, and instability of especially polyphenols with high molecular weights. Third, considerable emphasis was devoted to the essential polyphenol-microbiota interaction as polyphenols directly exert their regulatory effects on intestinal bacteria with concomitant biotransformation of polyphenols into metabolites by gut microbiota. This fundamental interplay provides the central explanation as to the stupefying pleiotropic biological/clinical actions and functions of “parent” polyphenols whereas their systemic bioavailability is incredibly limited, which highlights the prominent contribution of polyphenol metabolites. Fourth, the multifaceted actions and functions of “parent” polyphenols were summed up. Not only do polyphenols show the great ability to regulate cellular, molecular, and physiological pathways in relation with OxS and inflammation, but they also exhibit a remarkable effectiveness in improving cardiometabolic biomarkers to the advantage of human health. Thanks to their anti-obesogenic, -hyperlipidemic, -hypertensive, -IR, -atherosclerotic, as well as -diabetic effects, they may help to prevent and treat CMD as global public health problems with vast mortality and economic consequences. Fifth, although polyphenol metabolites were also shown to play a similar beneficial role in metabolic complications, there are various enigmatic issues to deal
with: inter-individual differences in the microbial conversion of parent polyphenols, largely unknown microbial metabolites from distinct polyphenols, unidentifiable bacterial strains involved, metabolite health-promoting effects of a multitude of metabolites, elusive metabolite doses, the underlying mechanisms of their specific actions, and the lack of clinical trials.

**Author Contributions:** Conceptualization, E.L. and E.D.; methodology, E.L.; validation, E.L. and E.D.; resources, E.L.; data curation, M.K., F.F. and E.D.; writing—original draft preparation, E.D. and E.L.; writing—review and editing, S.S., Y.D. and E.L.; supervision, E.L.; project administration, S.S.; funding acquisition, E.L. and Y.D. All authors have read and agreed to the published version of the manuscript.

**Funding:** This work was supported by a grant from the JA deSeve Research Chair in nutrition (E.L.) and the NSERC-Diana Food Industrial Chair on prebiotic effects of polyphenols (401240871) (E.L. & Y.D.).

**Conflicts of Interest:** The authors declare no conflict of interest.

**Abbreviations**

CMD: cardiometabolic disorders; CVD: cardiovascular disease; DAPP: dried apple peels; ERK: extracellular regulated kinases; GI: gastrointestinal; HPAA: phenylacetic acids; HPPA: phenylpropionic acid; IL: interleukin; IPEC: intestinal porcine enterocyte cell line; IR: insulin resistance; MetS: Metabolic syndrome; miRNAs: micro-RNAs; NF-κB: nuclear factor-kappa B; Nrf2: nuclear redox factor-2; OxS: oxidative stress; ROS: reactive oxygen species; TNFα: tumor necrosis factor-alpha.

**References**

1. Chen, Y.; Huang, L.; Liang, X.; Dai, P.; Zhang, Y.; Li, B.; Lin, X.; Sun, C. Enhancement of polyphenolic metabolism as an adaptive response of lettuce (Lactuca sativa) roots to aluminum stress. *Environ. Pollut.* 2020, 261, 114230. [CrossRef]
2. Czerniewicz, P.; Szytkiewicz, H.; Durak, R.; Borowiak-Sobkowiak, B.; Chrzanowski, G. Role of phenolic compounds during antioxidative responses of winter triticale to aphid and beetle attack. *Plant Physiol. Biochem.* 2017, 118, 529–540. [CrossRef]
3. Mestar, N.G.; Boudiaf, M.N.; Lahcene, S.; Abbaci, H.; Aiche, G.I.; Metna, B.; Saadoun, N.S.; Taibi, F.; Houali, K. Bio-insecticidal effects of Oleaster leaves aqueous extracts against *Psylla* larvae (*Euphyllura olivina* (Costa)), a primary pest of *Olea europaea* L. *Cell Mol. Biol.* 2018, 64, 35–40. [CrossRef]
4. Antonioli, A.; Fontana, A.R.; Piccoli, P.; Bottini, R. Characterization of polyphenols and evaluation of antioxidant capacity in grape pomace of the cv. Malbec. *Food Chem.* 2015, 178, 172–178. [CrossRef]
5. Anhe, F.F.; Roy, D.; Pilon, G.; Dudonne, S.; Matamoros, S.; Varin, T.V.; Garofalo, C.; Moine, Q.; Desjardins, Y.; Levy, E.; et al. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. *Gut* 2015, 64, 872–883. [CrossRef]
6. D’Amore, S.; Vacca, M.; Cariello, M.; Graziano, G.; D’Orazio, A.; Salvia, R.; Sasso, R.C.; Sabha, C.; Palasciano, G.; Moschetta, A. Genes and miRNA expression signatures in peripheral blood mononuclear cells in healthy subjects and patients with metabolic syndrome after acute intake of extra virgin olive oil. *Biochim. Biophys. Acta* 2016, 1861, 1671–1680. [CrossRef][PubMed]
7. Kantartzis, K.; Fritsche, L.; Bombrich, M.; Machann, J.; Schick, F.; Staiger, H.; Kunz, I.; Schoep, R.; Lehn-Stefan, A.; Heni, M.; et al. Effects of resveratrol supplementation on liver fat content in overweight and insulin-resistant subjects: A randomized, double-blind, placebo-controlled clinical trial. *Diabet. Obes. Metab.* 2018, 20, 1793–1797. [CrossRef]
8. Paquette, M.; Medina Larque, A.S.; Weisnagel, S.J.; Desjardins, Y.; Marois, J.; Pilon, G.; Dudonne, S.; Marette, A.; Jacques, H. Strawberry and cranberry polyphenols improve insulin sensitivity in insulin-resistant, non-diabetic adults: A parallel, double-blind, controlled and randomised clinical trial. *Br. J. Nutr.* 2017, 117, 519–531. [CrossRef]
9. Babu, P.V.A.; Liu, D.; Gilbert, E.R. Recent advances in understanding the anti-diabetic actions of dietary flavonoids. *J. Nutr. Biochem.* 2013, 24, 1777–1789. [CrossRef]
10. Dominguez Avila, J.A.; Rodrigo Garcia, J.; Gonzalez Aguilar, G.A.; de la Rosa, L.A. The Antidiabetic Mechanisms of Polyphenols Related to Increased Glucagon-Like Peptide-1 (GLP1) and Insulin Signaling. *Molecules* 2017, 22, 903. [CrossRef]
11. Les, F.; Casedas, G.; Gomez, C.; Moliner, C.; Valero, M.S.; Lopez, V. The role of anthocyanins as antidiabetic agents: From molecular mechanisms to in vivo and human studies. J. Physiol. Biochem. 2020. [CrossRef] [PubMed]

12. Macho-Gonzalez, A.; Lopez-Oliva, M.E.; Merino, J.J.; Garcia-Fernandez, R.A.; Garcia-Martín, A.; Redondo-Castillejo, R.; Bastida, S.; Sanchez-Muniz, F.J.; Benedit, J. Carob fruit extract-enriched meat improves pancreatic beta-cell dysfunction, hepatic insulin signaling and lipogenesis in late-stage type 2 diabetes mellitus model. J. Nutr. Biochem. 2020, 84, 108461. [CrossRef] [PubMed]

13. Wang, S.; Moustaid-Moussa, N.; Chen, L.; Mo, H.; Shastri, A.; Su, R.; Bapat, P.; Kwun, I.; Shen, C.L. Novel insights of dietary polyphenols and obesity. J. Nutr. Biochem. 2014, 25, 1–18. [CrossRef] [PubMed]

14. Cho, Y.J.; Lee, H.G.; Seo, K.H.; Yokoyama, W.; Kim, H. Antioxidant activity of Brazilian nuts. Antioxidants 2020, 9, 34 of 50. [CrossRef]

15. Sandovaal, V.; Sanz-Lamora, H.; Arias, G.; Marrero, P.F.; Haro, D.; Relat, J. Metabolic Impact of Flavonoids Consumption in Obesity: From Central to Peripheral. Nutrients 2020, 12, 2393. [CrossRef]

16. Anhe, F.F.; Nachbar, R.T.; Varin, T.V.; Trottier, J.; Doudonne, S.; Le Barz, M.; Feutry, P.; Pilon, G.; Barbier, O.; Desjardins, Y.; et al. Treatment with camu camu (Myrciaria dubia) prevents obesity by altering the gut microbiota and increasing energy expenditure in diet-induced obese mice. Gut 2019, 68, 453–464. [CrossRef]

17. McKay, D.L.; Blumberg, J.B. Cranberries (Vaccinium macrocarpon) and cardiovascular disease risk factors. Nutr. Rev. 2007, 65, 490–502. [CrossRef]

18. Ruel, G.; Couillard, C. Evidences of the cardioprotective potential of fruits: The case of cranberries. Mol. Nutr. Food Res. 2007, 51, 692–701. [CrossRef]

19. Ruel, G.; Lapointe, A.; Pomerleau, S.; Couture, P.; Lemieux, S.; Lamarche, B.; Couillard, C. Evidence that cranberry juice may improve augmentation index in overweight men. Nutr. Res. 2013, 33, 41–49. [CrossRef]

20. Martinez-Gonzalez, M.A.; Gea, A.; Ruiz-Canela, M. The Mediterranean Diet and Cardiovascular Health. Circ. Res. 2019, 124, 779–798. [CrossRef]

21. Ferrari, C.K.B. Anti-atherosclerotic and cardiovascular protective benefits of Brazilian nuts. Front. Biosci. Schol Ed. 2020, 12, 38–56. [CrossRef]

22. Perez de Vega, M.J.; Moreno-Fernandez, S.; Pontes-Quero, G.M.; Gonzalez-Amor, M.; Vazquez-Lasa, B.; Sabater-Munoz, B.; Briones, A.M.; Aguilar, M.R.; Miguel, M.; Gonzalez-Muniz, R. Characterization of Novel Synthetic Polyphenols: Validation of Antioxidant and Vasculoprotective Activities. Antioxidants 2020, 9, 787. [CrossRef]

23. Devi, S.A.; Chamoli, A. Polyphenols as an Effective Therapeutic Intervention Against Cognitive Decline During Normal and Pathological Brain Aging. Adv. Exp. Med. Biol. 2020, 1260, 159–174.

24. Oppedisano, F.; Maiuolo, J.; Gliozzi, M.; Musolino, V.; Carresi, C.; Nucera, S.; Sicchitano, M.; Scarano, F.; Bosco, F.; Macri, R.; et al. The Potential for Natural Antioxidant Supplementation in the Early Stages of Neurodegenerative Disorders. Int. J. Mol. Sci. 2020, 21, 2618. [CrossRef]

25. Silva, R.F.M.; Pogacnik, L. Polyphenols from Food and Natural Products: Neuroprotection and Safety. Antioxidants 2020, 9, 61. [CrossRef]

26. Bensalem, J.; Dudonne, S.; Gaudout, D.; Servant, L.; Calon, F.; Desjardins, Y.; Laye, S.; Lafenetre, P.; Pallet, V. Polyphenol-rich extract from grape and blueberry attenuates cognitive decline and improves neuronal function in aged mice. J. Nutr. Sci. 2018, 7, e19. [CrossRef]

27. Mao, X.; Xiao, X.; Chen, D.; Yu, B.; He, J. Tea and Its Components Prevent Cancer: A Review of the Redox-Related Mechanism. Int. J. Mol. Sci. 2019, 20, 5249. [CrossRef]

28. Toric, J.; Markovic, A.K.; Brala, C.J.; Barbaric, M. Anticancer effects of olive oil polyphenols and their combinations with anticancer drugs. Acta Pharm. 2019, 69, 461–482. [CrossRef]

29. Abdelgawad, I.Y.; Grant, M.K.O.; Zordoky, B.N. Leveraging the Cardio-Protective and Anticancer Properties of Resveratrol in Cardio-Oncology. Nutrients 2019, 11, 627. [CrossRef] [PubMed]

30. Horne, J.R.; Vohl, M.C. Biological plausibility for interactions between dietary fat, resveratrol, ACE2, and SARS-CoV illness severity. Am. J. Physiol. Endocrinol. Metab. 2020, 318, e830–e833. [CrossRef]

31. Mani, J.S.; Johnson, J.B.; Steel, J.C.; Broszczak, D.A.; Neilsen, P.M.; Walsh, K.B.; Naicker, M. Natural product-derived phytochemicals as potential agents against coronaviruses: A review. Virus Res. 2020, 284, 197989. [CrossRef]
32. Levy, E.; Delvin, E.; Marcil, V.; Spahis, S. May phytotherapy with polyphenols serve as a powerful approach for the prevention and therapy of novel coronavirus disease 2019 (Covid-19)? *Am. J. Physiol. Endocrinol. Metab.* **2020**, *319*. [CrossRef]

33. Dabeek, W.M.; Marra, M.V. Dietary Quercetin and Kaempferol: Bioavailability and Potential Cardiovascular-Related Bioactivity in Humans. *Nutrients* **2019**, *11*, 2288. [CrossRef]

34. Rechner, A.R.; Kuhnle, G.; Bremner, P.; Hubbard, G.P.; Moore, K.P.; Rice-Evans, C.A. The metabolic fate of dietary polyphenols in humans. *Free Radic. Biol. Med.* **2002**, *33*, 220–235. [CrossRef]

35. D’Archivio, M.; Filesi, C.; Vari, R.; Scacciazzoo, B.; Masella, R. Bioavailability of the polyphenols: Status and controversies. *Int. J. Mol. Sci.* **2010**, *11*, 1321–1342. [CrossRef]

36. Brglez Mojzer, E.; Knez Hrncic, M.; Skerget, M.; Knez, Z.; Bren, U. Polyphenols: Extraction Methods, Antioxidative Action, Bioavailability and Anticarcinogenic Effects. *Molecules* **2016**, *21*, 901. [CrossRef]

37. Kawabata, K.; Yoshioka, Y.; Terao, J. Role of Intestinal Microbiota in the Bioavailability and Physiological Functions of Dietary Polyphenols. *Molecules* **2019**, *24*, 370. [CrossRef]

38. Cardona, F.; Andrés-Lacueva, C.; Tulipani, S.; Tintahones, F.J.; Queipo-Ortuño, M.I. Benefits of polyphenols on gut microbiota and implications in human health. *J. Nutr. Biochem.* **2013**, *24*, 1415–1422. [CrossRef]

39. Bravo, L. Polyphenols: Chemistry, dietary sources, metabolism, and nutritional significance. *Nutr. Rev.* **1998**, *56*, 317–333. [CrossRef]

40. Crozier, A.; Jaganath, I.B.; Cliftord, M.N. Dietary phenolics: Chemistry, bioavailability and effects on health. *Nat. Prod. Rep.* **2009**, *26*, 1001–1043. [CrossRef]

41. Tsao, R. Chemistry and biochemistry of dietary polyphenols. *Nutrients* **2010**, *2*, 1231–1246. [CrossRef]

42. Smeriglio, A.; Barreca, D.; Bellocco, E.; Trombetta, D. Proanthocyanidins and hydrolysable tannins: Occurrence, dietary intake and pharmacological effects. *Br. J. Pharmacol.* **2017**, *174*, 1244–1262. [CrossRef]

43. Prigent, S.V.; Gruppen, H.; Visser, A.J.; Van Koningsveld, G.A.; Voragen, A.G. Effects of non-covalent interactions with 5-O-cafeoylquinic acid (chlorogenic acid) on the heat denaturation and solubility of globular proteins. *J. Agric. Food Chem.* **2003**, *51*, 5088–5095. [CrossRef]

44. Prigent, S.V.; Voragen, A.G.; Li, F.; Visser, A.J.; van Koningsveld, G.A.; Gruppen, H. Covalent interactions between amino acid side chains and oxidation products of cafeoylquinic acid (chlorogenic acid). *J. Sci. Food Agric.* **2008**, *88*, 1748–1754. [CrossRef]

45. Le Bourvellec, C.; Renard, C.M. Interactions between polyphenols and macromolecules: Quantification methods and mechanisms. *Crit. Rev. Food Sci. Nutr.* **2012**, *52*, 213–248. [CrossRef]

46. Kevers, C.; Pincemail, J.; Tabart, J.; Defraigne, J.O.; Dommes, J. Influence of cultivar, harvest time, storage conditions, and peeling on the antioxidant capacity and phenolic and ascorbic acid contents of apples and pears. *J. Agric. Food Chem.* **2011**, *59*, 6165–6171. [CrossRef] [PubMed]

47. Gomez-Rico, A.; Salvador, M.D.; La Greca, M.; Fregapane, G. Phenolic and volatile compounds of extra virgin olive oil (Olea europaea L. Cv. Cornicabra) with regard to fruit ripening and irrigation management. *J. Agric. Food Chem.* **2006**, *54*, 7130–7136. [CrossRef]

48. Bonoli, M.; Bendini, A.; Cerretani, L.; Lercker, G.; Toschi, T.G. Qualitative and semi-quantitative analysis of phenolic compounds in extra virgin olive oil (Olea europaea L Cv. Cornicabra) as a function of the ripening degree of olive fruits by different analytical techniques. *J. Agric. Food Chem.* **2004**, *52*, 7026–7032. [CrossRef]

49. Yao, L.H.; Jiang, Y.M.; Shi, J.; Tomas-Barberan, F.A.; Datta, N.; Singanusong, R.; Chen, S.S. Flavonoids in food and their health benefits. *Plant Foods Hum. Nutr.* **2004**, *59*, 113–122. [CrossRef]

50. Marti, M.P.; Pantaleon, A.; Rozek, A.; Soler, A.; Valls, J.; Macia, A.; Romero, M.P.; Motilva, M.J. Rapid analysis of procyanidins and anthocyanins in plasma by microelution SPE and ultra-HPLC. *J. Sep. Sci.* **2010**, *33*, 2841–2853. [CrossRef]

51. Denis, M.C.; Dubé, P.; Dudonné, S.; Desjardins, Y.; Matei, C.; Delvin, E.; Levy, E.; Furtos, A. Characterization of bioactive cranberry fractions by mass spectrometry. *Can. J. Chem.* **2020**, in press. [CrossRef]

52. Meng, X.; Maliaikal, P.; Lu, H.; Lee, M.J.; Yang, C.S. Urinary and plasma levels of resveratrol and quercetin in humans, mice, and rats after ingestion of pure compounds and grape juice. *J. Agric. Food Chem.* **2004**, *52*, 935–942. [CrossRef]

53. Vallejo, F.; Tomas-Barberan, F.; Garcia-Viguera, C. Health-promoting compounds in broccoli as influenced by refrigerated transport and retail sale period. *J. Agric. Food Chem.* **2003**, *51*, 3029–3034. [CrossRef]
54. Xu, B.; Chang, S.K. Total Phenolic, Phenolic Acid, Anthocyanin, Flavan-3-ol, and Flavonol Profiles and Antioxidant Properties of Pinto and Black Beans (Phaseolus vulgaris L.) as Affected by Thermal Processing. J. Agric. Food Chem. 2009, 57, 4754–4764. [CrossRef] [PubMed]
55. Khatoon, M.; Eguchi, S.; Yamaguchi, T.; Takamura, H.; Matoba, T. Effect of Thermal Treatment on Radical-scavenging Activity of Some Spices. Food Sci. Technol. Res. 2006, 12, 178–185. [CrossRef]
56. Azuma, K.; Ippoushi, K.; Ito, H.; Higashio, H.; Terao, J. Combination of lipids and emulsifiers enhances the absorption of orally administered quercetin in rats. J. Agric. Food Chem. 2002, 50, 1706–1712. [CrossRef]
57. Visioli, F.; Galli, C.; Grande, S.; Colonnelli, K.; Patelli, C.; Galli, G.; Caruso, D. Hydroxytyrosol excretion differs between rats and humans and depends on the vehicle of administration. J. Nutr. 2003, 133, 2612–2615. [CrossRef] [PubMed]
58. Williamson, G.; Kay, C.D.; Crozier, A. The Bioavailability, Transport, and Bioactivity of Dietary Flavonoids: A Review from a Historical Perspective. Compr. Rev. Food Sci. Food Saf. 2018, 17, 1054–1112. [CrossRef]
59. Pérez-Jiménez, J.; Hubert, J.; Hooper, L.; Cassidy, A.; Manach, C.; Williamson, G.; Scalbert, A. Urinary metabolites as biomarkers of polyphenol intake in humans: A systematic review. Am. J. Clin. Nutr. 2010, 92, 801–809. [CrossRef]
60. Manach, C.; Scalbert, A.; Morand, C.; Remesy, C.; Jimenez, L. Polyphenols: Food sources and bioavailability. Am. J. Clin. Nutr. 2004, 79, 727–747. [CrossRef]
61. Gonthier, M.P.; Donovan, J.L.; Texier, O.; Felgines, C.; Remesy, C.; Scalbert, A. Metabolism of dietary procyanidins in rats. Free Radic. Biol. Med. 2003, 35, 837–844. [CrossRef]
62. Chen, Z.; Zheng, S.; Li, L.; Jiang, H. Metabolism of flavonoids in human: A comprehensive review. Curr. Drug Metab. 2014, 15, 48–61. [CrossRef]
63. Villa-Rodriguez, J.A.; Ifie, I.; Gonzalez-Aguilar, G.A.; Roopchand, D.E. The Gastrointestinal Tract as Prime Site for Cardiometabolic Protection by Dietary Polyphenols. Adv. Nutr. 2019, 10, 999–1011. [CrossRef]
64. Spencer, J.P.; Chaudry, F.; Pannala, A.S.; Srai, S.K.; Debnam, E.; Rice-Evans, C. Decomposition of cocoa procyanidins in the gastric milieu. Biochem. Biophys. Res. Commun. 2000, 272, 236–241. [CrossRef] [PubMed]
65. Zhu, Q.Y.; Holt, R.R.; Lazarus, S.A.; Ersunsa, J.L.; Hammerstone, J.F.; Schmitz, H.H.; Keen, C.L. Stability of the flavan-3-ols epicatechin and catechin and related dimeric procyanidins derived from cocoa. J. Agric. Food Chem. 2002, 50, 1700–1705. [CrossRef] [PubMed]
66. Corona, G.; Tzounis, X.; Assunta Dessi, M.; Deiana, M.; Debnam, E.S.; Visioli, F.; Spencer, J.P. The fate of olive oil polyphenols in the gastrointestinal tract: Implications of gastric and colonic microflora-dependent biotransformation. Free Radic. Res. 2006, 40, 647–658. [CrossRef] [PubMed]
67. Serra, A.; Macia, A.; Romero, M.P.; Valls, J.; Blade, C.; Arola, L.; Motilva, M.J. Bioavailability of procyanidin dimers and trimers and matrix food effects in in vitro and in vivo models. Br. J. Nutr. 2010, 103, 944–952. [CrossRef] [PubMed]
68. Kahle, K.; Kempf, M.; Schreier, P.; Scheppach, W.; Schrenk, D.; Kautenburger, T.; Hecker, D.; Huemmer, W.; Ackermann, M.; Richling, E. Intestinal transit and systemic metabolism of apple polyphenols. Eur. J. Nutr. 2011, 50, 507–522. [CrossRef]
69. Van Rijmenant, E.; Salden, B.; Voorspoels, S.; Jacobs, G.; Noten, B.; Pitart, J.; Possemiers, S.; Smagghe, G.; Grootaert, C.; Van Camp, J. A Critical Evaluation of In Vitro Hesperidin 2S Bioavailability in a Model Combining Luminal (Microbial) Digestion and Caco-2 Cell Absorption in Comparison to a Randomized Controlled Human Trial. Mol. Nutr. Food Res. 2018, 62, e1700881. [CrossRef]
70. Hu, X.P.; Yin, F.W.; Zhou, D.Y.; Xie, H.K.; Zhu, B.W.; Ma, X.C.; Tian, X.G.; Wang, C.; Shahidi, F. Stability of resveratrol esters with caprylic acid during simulated in vitro gastrointestinal digestion. Food Chem. 2019, 276, 675–679. [CrossRef]
71. Liu, D.; Dhital, S.; Wu, P.; Chen, X.D.; Gidley, M.J. In Vitro Digestion of Apple Tissue Using a Dynamic Stomach Model: Grinding and Crushing Effects on Polyphenol Bioaccessibility. J. Agric. Food Chem. 2020, 68, 574–583. [CrossRef] [PubMed]
72. Ma, T.; Lan, T.; Geng, T.; Ju, Y.; Cheng, G.; Que, Z.; Gao, F.; Fang, Y.; Sun, X. Nutritional properties and biological activities of kiwifruit (Actinidia) and kiwifruit products under simulated gastrointestinal in vitro digestion. Food Nutr. Res. 2019, 63. [CrossRef] [PubMed]
73. Rios, L.Y.; Bennett, R.N.; Lazarus, S.A.; Remesy, C.; Scalbert, A.; Williamson, G. Cocoa procyanidins are stable during gastric transit in humans. Am. J. Clin. Nutr. 2002, 76, 1106–1110. [CrossRef] [PubMed]
74. Konishi, Y.; Zhao, Z.; Shimizu, M. Phenolic acids are absorbed from the rat stomach with different absorption rates. *J. Agric. Food Chem.* 2006, 54, 7539–7543. [CrossRef]

75. Pforte, H.; Hempel, J.; Jacobsch, G. Distribution pattern of a flavonoid extract in the gastrointestinal lumen and wall of rats. *Nahrung* 1999, 43, 205–208. [CrossRef]

76. Piskula, M.K.; Yamakoshi, J.; Iwai, Y. Daidzein and genistein but not their glucosides are absorbed from the rat stomach. *FEBS Lett.* 1999, 447, 287–291. [CrossRef]

77. Crespy, V.; Morand, C.; Besson, C.; Manach, C.; Demigne, C.; Remesy, C. Quercetin, but not its glycosides, is absorbed from the rat stomach. *J. Agric. Food Chem.* 2002, 50, 618–621. [CrossRef]

78. Gil-Izquierdo, A.; Zafirilla, P.; Tomás-Barberán, F.A. An in vitro method to simulate phenolic compound release from the food matrix in the gastrointestinal tract. *Eur. Food Res. Technol.* 2002, 214, 155–159. [CrossRef]

79. Ortega, N.; Reguant, J.; Romero, M.P.; Macia, A.; Motilva, M.J. Effect of fat content on the digestibility and bioaccessibility of cocoa polyphenol by an in vitro digestion model. *J. Agric. Food Chem.* 2009, 57, 5743–5749. [CrossRef]

80. Tsai, Y.M.; Chang-Liao, W.L.; Chien, C.F.; Lin, L.C.; Tsai, T.H. Effects of polymer molecular weight on relative oral bioavailability of curcumin. *Int. J. Nanomed.* 2012, 7, 2957–2966. [CrossRef]

81. Day, A.J.; Gee, J.M.; DuPont, M.S.; Johnson, I.T.; Williamson, G. Absorption of quercetin-3-glucoside and quercetin-4'-glucoside in the rat small intestine: The role of lactase phlorizin hydrolase and the sodium-dependent glucose transporter. *Biochem. Pharmacol.* 2003, 65, 1199–1206. [CrossRef]

82. Henry-Vitrac, C.; Desmouliere, A.; Girard, D.; Merillon, J.M. Transport, deglycosylation, and metabolism of trans-piceid by small intestinal epithelial cells. *Eur. J. Nutr.* 2006, 45, 376–382. [CrossRef]

83. Murota, K.; Nakamura, Y.; Uehara, M. Flavonoid metabolism: The interaction of metabolites and gut microbiota. *Biosci. Biotechnol. Biochem.* 2018, 82, 600–610. [CrossRef] [PubMed]

84. Murota, K.; Shimizu, S.; Chujo, H.; Moon, J.-H.; Terao, J. Effects of polymer molecular weight on relative oral bioavailability of curcumin. *Int. J. Nanomed.* 2012, 7, 2957–2966. [CrossRef] [PubMed]

85. Amaretti, A.; Raimondi, S.; Leonardi, A.; Quartieri, A.; Rossi, M. Hydrolysis of the rutinoside-conjugates flavonoids rutin and hesperidin by the gut microbiota and bifidobacteria. *Nutrients* 2015, 7, 2788–2800. [CrossRef] [PubMed]

86. Song, Q.; Li, D.; Zhou, Y.; Yang, J.; Yang, W.; Zhou, G.; Wen, J. Enhanced uptake and transport of (+)-catechin and (−)-epigallocatechin gallate in niosomal formulation by human intestinal Caco-2 cells. *Int. J. Nanomed.* 2014, 9, 2157–2165. [CrossRef]

87. Borges, G.; Ottaviani, J.I.; van der Hooft, J.J.; Schroeter, H.; Crozier, A. Absorption, metabolism, distribution and excretion of (−)-epicatechin: A review of recent findings. *Mol. Asp. Med.* 2018, 61, 18–30. [CrossRef]

88. Levy, E.; Yotov, W.; Seidman, E.G.; Garofalo, C.; Delvin, E.; Menard, D. Caco-2 cells and human fetal colon: A comparative analysis of their lipid transport. *Biochim. Biophys. Acta* 1999, 1439, 353–362. [CrossRef]

89. Nauli, S.M.; Nauli, S.M. Intestinal transport as a potential determinant of drug bioavailability. *Curr. Clin. Pharmacol.* 2013, 8, 247–255. [CrossRef]

90. Kern, S.M.; Bennett, R.N.; Needs, P.W.; Mellon, F.A.; Kroon, P.A.; Garcia-Conesa, M.T. Characterization of metabolites of hydroxycinnamates in the in vitro model of human small intestinal epithelium caco-2 cells. *J. Agric. Food Chem.* 2003, 51, 7884–7891. [CrossRef]

91. Hu, J.N.; Zhou, X.G.; He, Y.; Chen, F.; Deng, Z.Y. Esterification of Quercetin Increases Its Transport across Human Caco-2 Cells. *J. Food Sci.* 2016, 81, H1825–H1832. [CrossRef] [PubMed]

92. Su, H.F.; Lin, Q.; Wang, X.Y.; Fu, Y.; Gong, T.; Sun, X.; Zhang, Z.R. Absorptive interactions of concurrent oral administration of (+)-catechin and puerarin in rats and the underlying mechanisms. *Acta Pharmacol. Sin.* 2016, 37, 545–554. [CrossRef] [PubMed]

93. Dudonne, S.; Dal-Pan, A.; Dube, P.; Varin, T.V.; Calon, F.; Desjardins, Y. Potentiation of the bioavailability of blueberry phenolic compounds by co-ingested grape phenolic compounds in mice, revealed by targeted metabolomic profiling in plasma and feces. *Food Funct.* 2016, 7, 3421–3430. [CrossRef] [PubMed]
94. Dudonne, S.; Dube, P.; Pilon, G.; Marette, A.; Jacques, H.; Weisnagel, A.; Desjardins, Y. Modulation of Strawberry/Cranberry Phenolic Compounds Glucuronidation by Co-Supplementation with Onion: Characterization of Phenolic Metabolites in Rat Plasma Using an Optimized muSPE-UHPLC-MS/MS Method. J. Agric. Food Chem. 2014, 62, 3244–3256. [CrossRef]
95. Deglaire, A.; Moughan, P.J. Animal models for determining amino acid digestibility in humans—A review. Br. J. Nutr. 2012, 108 (Suppl. S2), S273–S281. [CrossRef]
96. Vergauwen, H. The IPEC-J2 Cell Line. In The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models; Verhoeckx, K., Cotter, P., López-Expósito, I., Kleiveland, C., Lea, T., Mackie, A., Requena, T., Swiatecka, D., Wichers, H., Eds.; Springer International Publishing: Cham, Switzerland, 2015; pp. 125–134.
97. Chedea, V.S.; Palade, L.M.; Marin, D.E.; Pelmus, R.S.; Habeanu, M.; Rotar, M.C.; Gras, M.A.; Pistol, G.C.; Tararu, I. Intestinal Absorption and Antioxidant Activity of Grape Pomace Polyphenols. Nutrients 2018, 10, 588. [CrossRef]
98. Wang, W.; Sun, C.; Mao, L.; Ma, P.; Liu, F.; Yang, J.; Gao, Y. The biological activities, chemical stability, metabolism and delivery systems of quercetin: A review. Trends Food Sci. Tech. 2016, 56, 21–38. [CrossRef]
99. Zhang, L.; Wang, Y.; Li, D.; Ho, C.T.; Li, J.; Wan, X. The absorption, distribution, metabolism and excretion of procyanidins. Food Funct. 2016, 7, 1273–1281. [CrossRef]
100. Rothwell, J.A.; Urpi-Sarda, M.; Llorach, R.; Farran-Codina, A.; Barupal, D.K.; Neveu, V.; Manach, C.; Andres-Lacueva, C.; Scalbert, A. Systematic analysis of the polyphenol metabolome using the Phenol-Explorer database. Mol. Nutr. Food Res. 2016, 60, 203–211. [CrossRef]
101. Martínez-Maqueda, D.; Miralles, B.; Recio, I. HT29 Cell Line. In The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models; Verhoeckx, K., Cotter, P., López-Expósito, I., Kleiveland, C., Lea, T., Mackie, A., Requena, T., Swiatecka, D., Wichers, H., Eds.; Springer International Publishing: Cham, Switzerland, 2015; pp. 113–124.
102. Bergmann, H.; Rogoll, D.; Scheppach, W.; Melcher, R.; Richling, E. The Ussing type chamber model to study the intestinal transport and modulation of specific tight-junction genes using a colonic cell line. Mol. Nutr. Food Res. 2009, 53, 1211–1225. [CrossRef]
103. Alsolmei, F.A.; Li, H.; Pereira, S.L.; Krishnan, P.; Johns, P.W.; Siddiqui, R.A. Polyphenol-Enriched Plum Extract Enhances Myotubule Formation and Anabolism while Attenuating Colon Cancer-induced Cellular Damage in C2C12 Cells. Nutrients 2019, 11, 1077. [CrossRef]
104. Blanquer-Rossello, M.D.; Hernandez-Lopez, R.; Rocas, P.; López-Expósito, I., Kleiveland, C., Lea, T., Mackie, A., Requena, T., Swiatecka, D., Wichers, H., Eds.; Springer International Publishing: Cham, Switzerland, 2015; pp. 113–124.
105. Martínez-Maqueda, D.; Miralles, B.; Recio, I. HT29 Cell Line. In The Impact of Food Bioactives on Health: In Vitro and Ex Vivo Models; Verhoeckx, K., Cotter, P., López-Expósito, I., Kleiveland, C., Lea, T., Mackie, A., Requena, T., Swiatecka, D., Wichers, H., Eds.; Springer International Publishing: Cham, Switzerland, 2015; pp. 113–124.
106. Valdes, A.; Garcia-Canas, V.; Simo, C.; Ibanez, C.; Micol, V.; Ferragut, J.A.; Cifuentes, A. Comprehensive foodomics study on the mechanisms operating at various molecular levels in cancer cells in response to individual rosemary polyphenols. Anal. Chem. 2016, 88, 9807–9815. [CrossRef]
107. Williamson, G.; Clifford, M.N. Role of the small intestine, colon and microbota in determining the metabolic fate of polyphenols. Biochem. Pharmacol. 2017, 139, 24–39. [CrossRef]
108. Marin, L.; Miguelez, E.M.; Villar, C.J.; Lombo, F. Bioavailability of dietary polyphenols and gut microbiota metabolism: Antimicrobial properties. Biomed. Res. Int. 2015, 2015, 905215. [CrossRef]
109. Monagas, M.; Urpi-Sarda, M.; Sanchez-Patan, F.; Llorach, R.; Garrido, I.; González-Cordoves, C.; Andres-Lacueva, C.; Bartolome, B. Insights into the metabolism and microbial biotransformation of dietary flavan-3-ols and the bioactivity of their metabolites. Food Funct. 2010, 1, 233–253. [CrossRef]
110. Neish, A.S. Microbes in gastrointestinal health and disease. Gastroenterology 2009, 136, 65–80. [CrossRef]
111. Arora, T.; Backhed, F. The gut microbiota and metabolic disease: Current understanding and future perspectives. J. Intern. Med. 2016, 280, 339–349. [CrossRef]
112. Korpela, K. Diet, Microbiota, and Metabolic Health: Trade-Off between Saccharolytic and Proteolytic Fermentation. Annu. Rev. Food Sci. Technol. 2018, 9, 65–84. [CrossRef]
113. Ma, N.; Tian, Y.; Wu, Y.; Ma, X. Contributions of the Interaction Between Dietary Protein and Gut Microbiota to Intestinal Health. Curr. Protein Pept. Sci. 2017, 18, 795–808. [CrossRef]
114. Zhao, J.; Zhang, X.; Liu, H.; Brown, M.A.; Qiao, S. Dietary Protein and Gut Microbiota Composition and Function. *Curr. Protein Pept. Sci.* 2019, 20, 145–154. [CrossRef]

115. Qin, J.; Li, R.; Raes, J.; Arumugam, M.; Burgdorf, K.S.; Manichanh, C.; Nielsen, T.; Pons, N.; Levenez, F.; Yamada, T.; et al. Human gut microbial gene catalogue established by metagenomic sequencing. *Nature* 2010, 464, 62–66. [CrossRef]

116. Ou, J.; Carbonero, F.; Zoetendal, E.G.; Delany, J.P.; Wang, M.; Newton, K.; Gaskins, H.R.; O’Keefe, S.J. Diet, microbiota, and microbial metabolites in colon cancer risk in rural Africans and African Americans. *Am. J. Clin. Nutr.* 2013, 98, 111–120. [CrossRef]

117. Wu, G.D.; Chen, J.; Hoffmann, C.; Bittinger, K.; Chen, Y.Y.; Keibbaugh, S.A.; Bewtra, M.; Knights, D.; Walters, W.A.; Knight, R.; et al. Linking long-term dietary patterns with gut microbial enterotypes. *Science* 2011, 334, 105–108. [CrossRef]

118. Zhermakova, A.; Kurilshikov, A.; Bonder, M.J.; Tigchelaar, E.F.; Schirmer, M.; Vatanen, T.; Mujagic, Z.; Vila, A.V.; Falony, G.; Vieira-Silva, S.; et al. Population-based metagenomics analysis reveals markers for gut microbiome composition and diversity. *Science* 2016, 352, 565–569. [CrossRef]

119. Kabeerdoss, J.; Devi, R.S.; Mary, R.R.; Ramakrishna, B.S. Faecal microbiota composition in vegetarians: Comparison with omnivores in a cohort of young women in southern India. *Br. J. Nutr.* 2012, 108, 953–957. [CrossRef]

120. De Filippo, C.; Cavalieri, D.; Di Paola, M.; Ramazzotti, M.; Poullet, J.B.; Massart, S.; Collini, S.; Pieraccini, G.; Lionetti, P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *Proc. Natl. Acad. Sci. USA* 2010, 107, 14691–14696. [CrossRef]

121. Walker, A.W.; Ince, J.; Duncan, S.H.; Webster, L.M.; Holtrop, G.; Ze, X.; Brown, D.; Stares, M.D.; Scott, P.; Bergerat, A.; et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. *ISME J.* 2011, 5, 220–230. [CrossRef]

122. Kumar Singh, A.; Cabral, C.; Kumar, R.; Ganguly, R.; Kumar Rana, H.; Gupta, A.; Rosaria Lauro, M.; Carbone, C.; Reis, F.; Pandey, A.K. Beneficial Effects of Dietary Polyphenols on Gut Microbiota and Strategies to Improve Delivery Efficiency. *Nutrients* 2019, 11, 2216. [CrossRef]

123. Yin, H.; Deng, Y.; Wang, H.; Liu, W.; Zhuang, X.; Chu, W. Tea polyphenols as an antivirulence compound Disrupt Quorum-Sensing Regulated Pathogenicity of Pseudomonas aeruginosa. *Sci. Rep.* 2015, 5, 16158. [CrossRef]

124. De Filippo, C.; Cavalieri, D.; Di Paola, M.; Ramazzotti, M.; Poullet, J.B.; Massart, S.; Collini, S.; Pieraccini, G.; Lionetti, P. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. *Proc. Natl. Acad. Sci. USA* 2010, 107, 14691–14696. [CrossRef]

125. Stenvang, M.; Dueholm, M.S.; Vad, B.S.; Seviour, T.; Zeng, G.; Geimann-Shochat, S.; Søndergaard, M.T.; Christiansen, G.; Meyer, R.L.; Kjelleberg, S.; et al. Epigallocatechin Gallate Remodels Overexpressed Functional Amyloids in Pseudomonas aeruginosa and Increases Biofilm Susceptibility to Antibiotic Treatment. *J. Biol. Chem.* 2016, 291, 26540–26553. [CrossRef]

126. Stapleton, P.D.; Shah, S.; Ehlerl, K.; Har, Y.; Taylor, P.W. The beta-lactam-resistance modifier (−)-epicatechin gallate alters the architecture of the cell wall of Staphylococcus aureus. *Microbiology* 2007, 153, 2093–2103. [CrossRef]

127. Hachimura, S.; Totsuka, M.; Hosono, A. Immunomodulation by food: Impact on gut immunity and immune cell function. *Biosci. Biotechnol. Biochem.* 2018, 82, 584–599. [CrossRef]

128. Vitetta, L.; Vitetta, G.; Hall, S. Immunological Tolerance and Function: Associations Between Intestinal Bacteria, Probiotics, Prebiotics, and Phages. *Front. Immunol.* 2018, 9, 2240. [CrossRef]

129. Stan, M.S.; Voicu, S.N.; Caruntu, S.; Nica, I.C.; Olah, N.K.; Burtescu, R.; Balta, C.; Rosu, M.; Herman, H.; Hermenean, A.; et al. Antioxidant and Anti-Inflammatory Properties of a Thuja occidentalis Mother Tincture Extract from Grape Seeds on Human Fecal Flora and Fecal Odor. *Microb. Ecol. Health Dis.* 2001, 13, 25–31.

130. Larroa, M.; Luceri, C.; Vivioli, E.; Pagliuca, C.; Lodovici, M.; Moneti, G.; Dolara, P. Polyphenol metabolites from colonic microbiota exert anti-inflammatory activity on different inflammation models. *Mol. Nutr. Food Res.* 2009, 53, 1044–1054. [CrossRef]
133. Tzounis, X.; Rodriguez-Mateos, A.; Vulevic, J.; Gibson, G.R.; Kwik-Uribe, C.; Spencer, J.P. Prebiotic evaluation of cocoa-derived flavanols in healthy humans by using a randomized, controlled, double-blind, crossover intervention study. *Am. J. Clin. Nutr.* **2011**, *93*, 62–72. [CrossRef]

134. Moreno-Indias, I.; Sánchez-Alcoholado, L.; Pérez-Martínez, P.; Andrés-Lacueva, C.; Cardona, F.; Tainohones, F.; Queipo-Ortuño, M.I. Red wine polyphenols modulate fecal microbiota and reduce markers of the metabolic syndrome in obese patients. *Food Funct.* **2016**, *7*, 1775–1787. [CrossRef]

135. Rowland, I.; Gibson, G.; Heiniken, A.; Scott, K.; Swann, J.; Thiele, I.; Tuohy, K. Gut microbiota functions: Metabolism of nutrients and other food components. *Eur. J. Nutr.* **2018**, *57*, 1–24. [CrossRef] [PubMed]

136. Braune, A.; Blaut, M. Bacterial species involved in the conversion of dietary flavonoids in the human gut. *Gut Microbes* **2016**, *7*, 216–234. [CrossRef]

137. Corrêa, T.A.F.; Rogerio, M.M.; Hassimotto, N.M.A.; Lajolo, F.M. The Two-Way Polyphenols-Microbiota Interactions and Their Effects on Obesity and Related Metabolic Diseases. *Front. Nutr.* **2019**, *6*, 188. [CrossRef]

138. Cote, A.T.; Harris, K.C.; Panagiotopoulos, C.; Sandor, G.G.; Devlin, A.M. Childhood obesity and cardiovascular dysfunction. *J. Am. Coll. Cardiol.* **2013**, *62*, 1309–1319. [CrossRef]

139. Levy, E.; Saenger, A.K.; Steffes, M.W.; Delvin, E. Pediatric Obesity and Cardiometabolic Disorders: Risk Factors and Biomarkers. *Eijfe.* **2017**, *28*, 6–24. [PubMed]

140. Nehus, E.; Mitsnefes, M. Childhood Obesity and the Metabolic Syndrome. *Pediatr. Clin. N. Am.* **2019**, *66*, 31–43. [CrossRef]

141. Vona, R.; Gambardella, L.; Cittadini, C.; Straface, E.; Pietrafort, D. Biomarkers of Oxidative Stress in Metabolic Syndrome and Associated Diseases. *Oxid. Med. Cell. Longev.* **2019**, *2019*, 8267234. [CrossRef] [PubMed]

142. Reinehr, T.; Roth, C.L. Inflammation Markers in Type 2 Diabetes and the Metabolic Syndrome in the Pediatric Population. *Curr. Diab. Rep.* **2018**, *18*, 131. [CrossRef]

143. Rani, V.; Deep, G.; Singh, R.K.; Palle, K.; Yadav, U.C.S. Oxidative stress and metabolic disorders: Pathogenesis and therapeutic strategies. *Life Sci.* **2016**, *148*, 183–193. [CrossRef] [PubMed]

144. McKeown, N.M.; Meigs, J.B.; Liu, S.; Saltzman, E.; Wilson, P.W.; Jacques, P.F. Carbohydrate nutrition, insulin resistance, and the prevalence of the metabolic syndrome in the Framingham Offspring Cohort. *Diabet. Care* **2004**, *27*, 538–546. [CrossRef] [PubMed]

145. Spahis, S.; Alvarez, F.; Ahmed, N.; Dubois, J.; Jalbout, R.; Paganelli, M.; Grzywacz, K.; Delvin, E.; Peretti, N.; Levy, E. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: Impact of omega-3 fatty acids. *J. Nutr. Biochem.* **2018**, *58*, 28–36. [CrossRef]

146. Sabaté, J.; Wien, M. A perspective on vegetarian dietary patterns and risk of metabolic syndrome. *Br. J. Nutr.* **2015**, *113* (Suppl. S2), S136–S143. [CrossRef] [PubMed]

147. Esmaillzadeh, A.; Mirmiran, P.; Azizi, F. Whole-grain consumption and the metabolic syndrome: A favorable association in Tehranian adults. *Eur. J. Clin. Nutr.* **2005**, *59*, 353–362. [CrossRef]

148. Mallappa, R.H.; Rokana, N.; Duary, R.K.; Panwar, H.; Batish, V.K.; Grover, S. Management of metabolic syndrome through probiotic and prebiotic interventions. *Indian J. Endocrinol. Metab.* **2012**, *16*, 20–27.

149. Joseph, S.V.; Edirisinghe, I.; Burton-Freeman, B.M. Fruit Polyphenols: A Review of Anti-inflammatory Effects in Humans. *Crit. Rev. Food Sci. Nutr.* **2016**, *56*, 419–444. [CrossRef]

150. Gourineni, V.; Shay, N.F.; Chung, S.; Sandhu, A.K.; Gu, L. Muscadine grape (*Vitis rotundifolia*) and wine phytochemicals prevented obesity-associated metabolic complications in C57BL/6 mice. *J. Agric. Food Chem.* **2012**, *60*, 7674–7681. [CrossRef]

151. Makino-Wakagi, Y.; Yoshimura, Y.; Uzawa, Y.; Zaima, N.; Moriyama, T.; Kawamura, Y. Ellagic acid in pomegranate suppresses resistin secretion by a novel regulatory mechanism involving the degradation of intracellular resistin protein in adipocytes. *Biochem. Biophys. Res. Commun.* **2012**, *417*, 880–885. [CrossRef]

152. Lei, F.; Zhang, X.N.; Wang, W.; Xing, D.M.; Xie, W.D.; Su, H.; Du, L.J. Evidence of anti-obesity effects of the pomegranate leaf extract in high-fat diet induced obese mice. *Int. J. Obes.* **2007**, *31*, 1023–1029. [CrossRef]

153. Monika, P.; Geetha, A. The modulating effect of *Persea americana* fruit extract on the level of expression of fatty acid synthase complex, lipoprotein lipase, fibroblast growth factor-21 and leptin—A biochemical study in rats subjected to experimental hyperlipidemia and obesity. *Phytomedicine* **2015**, *22*, 939–945. [CrossRef] [PubMed]

154. Kang, J.; Espin, J.C.; Carr, T.P.; Tomás-Barberán, F.A.; Chung, S. Raspberry seed flour attenuates high-sucrose diet-mediated hepatic stress and adipose tissue inflammation. *J. Nutr. Biochem.* **2016**, *32*, 64–72. [CrossRef] [PubMed]
155. Upadhyay, S.; Dixit, M. Role of Polyphenols and Other Phytochemicals on Molecular Signaling. *Oxid. Med. Cell. Longev.* **2015**, *2015*, 504253. [CrossRef] [PubMed]

156. Gothai, S.; Ganesan, P.; Park, S.Y.; Fukurazi, S.; Choi, D.K.; Arulselvan, P. Natural Phyto-Bioactive Compounds for the Treatment of Type 2 Diabetes: Inflammation as a Target. *Nutrients* **2016**, *8*, 461. [CrossRef] [PubMed]

157. Zhang, S.; Qin, C.; Safe, S.H. Flavonoids as aryl hydrocarbon receptor agonists and antagonists: E-Atom versus Elecron Transfer Mechanism. *J. Phys. Chem.* **2004**, *108*, 4916–4922. [CrossRef]

158. Kansanen, E.; Kuosmanen, S.M.; Leinonen, H.; Levonen, A.L. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. *Redox Biol.* **2013**, *1*, 45–49. [CrossRef] [PubMed]

159. Oteiza, P.I.; Erlejman, A.G.; Verstraeten, S.V.; Keen, C.L.; Fraga, C.G. Flavonoid-membrane interactions: A protective role of flavonoids at the membrane surface? *Clin. Dev. Immunol.* **2005**, *12*, 19–25. [CrossRef]

160. Perron, N.R.; Brumaghim, J.L. A review of the antioxidant mechanisms of polyphenol compounds related to iron binding. *Cell Biochem. Biophys.* **2009**, *53*, 75–100. [CrossRef]

161. Spahis, S.; Borys, J.M.; Levy, E. Metabolic Syndrome as a Multifaceted Risk Factor for Oxidative Stress. *Antioxid. Redox Signal.* **2017**, *26*, 445–461. [CrossRef]

162. Kansanen, E.; Kuosmanen, S.M.; Leinonen, H.; Levonen, A.L. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. *Redox Biol.* **2013**, *1*, 45–49. [CrossRef] [PubMed]

163. Kansanen, E.; Kuosmanen, S.M.; Leinonen, H.; Levonen, A.L. The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer. *Redox Biol.* **2013**, *1*, 45–49. [CrossRef] [PubMed]

164. Köhle, C.; Bock, K.W. Activation of coupled Ah receptor and Nrf2 gene batteries by dietary phytochemicals versus Elecgron Transfer Mechanism. *J. Phys. Chem.* **2004**, *108*, 4916–4922. [CrossRef]

165. Chuang, C.C.; McIntosh, M.K. Potential mechanisms by which polyphenol-rich grapes prevent obesity-mediated inflammation and metabolic diseases. *Annu. Rev. Nutr.* **2011**, *31*, 155–176. [CrossRef]

166. Diotallevi, C.; Fava, F.; Gobbetti, M.; Tuohy, K. Healthy dietary patterns to reduce obesity-related metabolic disease: Polyphenol: Microbiome interactions unifying health effects across geography. *Curr. Opin. Clin. Nutr. Metab. Care* **2020**, *23*, 437–444. [CrossRef]

167. Zhang, S.; Qin, C.; Safe, S.H. Flavonoids as aryl hydrocarbon receptor agonists/antagonists: Effects of structure and cell context. *Environ. Health Perspect.* **2003**, *111*, 1877–1882. [CrossRef] [PubMed]

168. Matsuno, Y.; Atsumi, Y.; Alauddin, M.; Rana, M.M.; Fujimori, H.; Hyodo, M.; Shimizu, A.; Ikuta, T.; Tani, H.; Torigoe, H.; et al. Resveratrol and its Related Polyphenols Contribute to the Maintenance of Genome Stability. *Sci. Rep.* **2020**, *10*, 5388. [CrossRef] [PubMed]

169. Huarte, E.; Cid, C.; Azqueta, A.; de Pena, M.P. DNA damage and DNA protection from digested raw and griddled green pepper (poly)phenols in human colorectal adenocarcinoma cells (HT-29). *Eur. J. Nutr.* **2020**, *60*, 2556–2570. [CrossRef] [PubMed]

170. Groh, I.A.M.; Bakuradze, T.; Pahlke, G.; Richling, E.; Marko, D. Consumption of anthocyanin-rich beverages affects Nrf2 and Nrf2-dependent gene transcription in peripheral lymphocytes and DNA integrity of healthy volunteers. *BMC Chem.* **2020**, *14*, 39. [CrossRef]

171. Abib, R.T.; Quinozoes-Santos, A.; Zanotto, C.; Zeidán-Chuliá, F.; Lunardi, P.S.; Gonçalves, C.A.; Gottfried, C. Genoprotective effects of the green tea-derived polyphenol/epicatechin gallate in C6 astroglial cells. *J. Med. Food* **2010**, *13*, 1111–1115. [CrossRef]

172. Quinozoes-Santos, A.; Andreazza, A.C.; Nardin, P.; Funchal, C.; Gonçalves, C.A.; Gottfried, C. Resveratrol attenuates oxidative-induced DNA damage in C6 Gloma cells. *Neurotoxicology* **2007**, *28*, 886–891. [CrossRef]

173. Han, K.C.; Wong, W.C.; Benzie, I.F. Genoprotective effects of green tea (Camellia sinensis) in human subjects: Results of a controlled supplementation trial. *Br. J. Nutr.* **2011**, *105*, 171–179. [CrossRef]

174. Morgan, M.J.; Liu, Z.G. Crosstalk of reactive oxygen species and NF-κB signaling. *Cell Res.* **2011**, *21*, 103–115. [CrossRef]

175. Blaser, H.; Dostert, C.; Mak, T.W.; Brenner, D. TNF and ROS Crosstalk in Inflammation. *Trends Cell. Biol.* **2016**, *26*, 249–261. [CrossRef] [PubMed]

176. Kim, Y.S.; Young, M.R.; Boe, G.; Colburn, N.H.; Milner, J.A. Bioactive food components, inflammatory targets, and cancer prevention. *Cancer Prev. Res.* **2009**, *2*, 200–208. [CrossRef] [PubMed]
Antioxidants 2020, 9, 982

178. Yu, Z.; Tang, Y.; Hu, D.; Li, J. Inhibitory effect of genistein on mouse colon cancer MC-26 cells involved TGF-beta1/Smad pathway. *Biochem. Biophys. Res. Commun.* 2005, 333, 827–832. [CrossRef] [PubMed]

179. Nguyen, K.A.; Cao, Y.; Chen, J.R.; Townsend, C.M., Jr.; Ko, T.C. Dietary fiber enhances a tumor suppressor signaling pathway in the gut. *Ann. Surg.* 2006, 243, 619–625. [CrossRef]

180. Denis, M.C.; Furtos, A.; Dudonne, S.; Montoudis, A.; Garofalo, C.; Desjardins, Y.; Delvin, E.; Levy, E. Apple peel polyphenols and their beneficial actions on oxidative stress and inflammation. *PLoS ONE* 2013, 8, e53725. [CrossRef]

181. Yeganeh, P.R.; Leahy, J.; Spahis, S.; Patey, N.; Desjardins, Y.; Roy, D.; Delvin, E.; Garofalo, C.; Leduc-Gaudet, J.P.; et al. Apple peel polyphenols reduce mitochondrial dysfunction in mice with DSS-induced ulcerative colitis. *J. Nutr. Biochem.* 2018, 57, 56–66. [CrossRef]

182. Denis, M.C.; Roy, D.; Yeganeh, P.R.; Desjardins, Y.; Varin, T.; Haddad, N.; Amre, D.; Sane, A.T.; Garofalo, C.; Furtos, A.; et al. Apple peel polyphenols: A key player in the prevention and treatment of experimental inflammatory bowel disease. *Clin. Sci.* 2016, 130, 2217–2237. [CrossRef]

183. Cheng, Z.; Zheng, L.; Almeida, F.A. Epigenetic reprogramming in metabolic disorders: Nutritional factors and beyond. *J. Nutr. Biochem.* 2018, 54, 1–10. [CrossRef]

184. Lim, W.-J.; Kim, K.H.; Kim, J.-Y.; Jeong, S.; Kim, N. Identification of DNA-Methylated CpG Islands Associated With Gene Silencing in the Adult Body Tissues of the Ogye Chicken Using RNA-Seq and Reduced Representation Bisulfite Sequencing. *Front. Genet.* 2019, 10, 346. [CrossRef]

185. Bannister, A.J.; Kouzarides, T. Regulation of chromatin by histone modifications. *Cell Res.* 2011, 21, 381–395. [CrossRef] [PubMed]

186. Moutinho, C.; Esteller, M. Chapter Seven—MicroRNAs and Epigenetics. In *Advances in Cancer Research*; Croce, C.M., Fisher, P.B., Eds.; Academic Press: Cambridge, MA, USA, 2017; Volume 135, pp. 189–220.

187. Bruce, K.D.; Cagampang, F.R. Epigenetic priming of the metabolic syndrome. *Mol. Nutr. Food Res.* 2019, 64, e1900995. [CrossRef] [PubMed]

188. Nettore, I.C.; Rocca, C.; Mancino, G.; Albano, L.; Amelio, D.; Grande, F.; Pasqua, T.; Desiderio, S.; Mazza, R.; et al. Quercetin and its derivative Q2 modulate chromatin dynamics in adipogenesis and Q2 prevents obesity and metabolic disorders in rats. *J. Nutr. Biochem.* 2019, 69, 151–162. [CrossRef] [PubMed]

189. Netto, E.C.; Solá, R.; Valls, R.M.; Caimari, A.; Del Bas, J.M.; Anguera, A.; Anglés, N.; Arola, L. Cocoa Consumption Alters the Global DNA Methylation of Peripheral Leukocytes in Humans with Cardiovascular Disease Risk Factors: A Randomized Controlled Trial. *PLoS ONE* 2013, 8, e65744. [CrossRef]

190. Boqué, N.; de la Iglesia, R.; de la Garza, A.L.; Milagro, F.I.; Olivares, O.; Bañuelos, O.; Soria, A.C.; Rodríguez-Sánchez, S.; Martínez, J.A.; Campión, J. Prevention of diet-induced obesity by apple polyphenols in Wistar rats through regulation of adipocyte gene expression and DNA methylation patterns. *Mol. Nutr. Food Res.* 2013, 57, 1473–1478. [CrossRef] [PubMed]

191. Crescenti, A.; Solà, R.; Valls, R.M.; Caimari, A.; Del Bas, J.M.; Anguera, A.; Anglés, N.; Arola, L. Cocoa Consumption Alters the Global DNA Methylation of Peripheral Leukocytes in Humans with Cardiovascular Disease Risk Factors: A Randomized Controlled Trial. *PLoS ONE* 2013, 8, e65744. [CrossRef]

192. Han, S.; Uludag, M.O.; Usanmaz, S.E.; Ayaloglu-Butun, F.; Akcali, K.C.; Demirel-Yilmaz, E. Resveratrol affects histone 3 lysine 27 methylation of vessels and blood biomarkers in DOCA salt-induced hypertension. *Mol. Biol. Rep.* 2015, 42, 35–42. [CrossRef]

193. Boesch-Saadatmandi, C.; Loboda, A.; Wagner, A.E.; Stachurska, A.; Jozkowicz, A.; Dulak, J.; Döring, F.; Wolffram, S.; Rimbach, G. Effect of quercetin and its metabolites isorhamnetin and quercetin-3-glucuronide on inflammatory gene expression: Role of miR-155. *J. Nutr. Biochem.* 2011, 22, 293–299. [CrossRef]

194. Tili, E.; Michaille, J.J.; Adair, B.; Alder, H.; Limagne, E.; Taccioli, C.; Ferracin, M.; Delmas, D.; Latruffe, N.; Croce, C.M. Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. *Carcinogenesis* 2010, 31, 1561–1566. [CrossRef] [PubMed]

195. Rasheed, Z.; Rasheed, N.; Al-Shobaili, H.A. Epigallocatechin-3-O-gallate up-regulates microRNA-199a-3p expression by down-regulating the expression of cyclooxygenase-2 in stimulated human osteoarthritic chondrocytes. *J. Cell. Mol. Med.* 2016, 20, 2241–2248. [CrossRef]
196. Carpi, S.; Scoditti, E.; Massaro, M.; Polini, B.; Manera, C.; Di Giacomo, M.; Esposito Salsano, J.; Poli, G.; Tuccinardi, T.; Doccini, S.; et al. The Extra-Virgin Olive Oil Polyphenols Oleocanthal and Oleacein Counteract Inflammation-Related Gene and miRNA Expression in Adipocytes by Attenuating NF-κB Activation. *Antioxidants* **2019**, *9*, 11, 2855. [CrossRef] [PubMed]

197. Scoditti, E.; Carpi, S.; Massaro, M.; Pellegrino, M.; Polini, B.; Carluccio, M.A.; Wabitsch, M.; Verri, T.; Nieri, P.; De Caterina, R. Hydroxytyrosol Modulates Adipocyte Gene and miRNA Expression Under Inflammatory Condition. *Antioxidants* **2019**, *9*, 11, 2493. [CrossRef] [PubMed]

198. Zaccaria, V.; Curti, V.; Di Lorenzo, A.; Baldi, A.; Maccario, C.; Sommatis, S.; Mochi, R.; Daglia, M. Effect of Green and Brown Propolis Extracts on the Expression Levels of microRNAs, mRNAs and Proteins, Related to Oxidative Stress and Inflammation. *Antioxidants* **2017**, *9*, 1090. [CrossRef]

199. Howell, J.C.; Chun, E.; Farrell, A.N.; Hur, E.Y.; Caroti, C.M.; Iuvone, P.M.; Haque, R. Global microRNA expression profiling: Curcumin (diferuloylmethane) alters oxidative stress-responsive microRNAs in human ARPE-19 cells. *Mol. Vis.* **2013**, *19*, 544–560.

200. Noratto, G.D.; Angel-Morales, G.; Talcott, S.T.; Mertens-Talcott, S.U. Polyphenolics from *Euterpe oleracea* Mart. and red muscadine grape (*Vitis rotundifolia*) protect human umbilical vascular Endothelial cells (HUVEC) from glucose- and lipopolysaccharide (LPS)-induced inflammation and target microRNA-126. *J. Agric. Food Chem.* **2011**, *59*, 7999–8012. [CrossRef]

201. Song, J.; Jun, M.; Ahn, M.R.; Kim, O.Y. Involvement of miR-Let7A in inflammatory response and cell survival/apoptosis regulated by resveratrol in THP-1 macrophage. *Nutr. Res. Pract.* **2016**, *10*, 377–384. [CrossRef]

202. Boesch-Saadatmandi, C.; Wagner, A.E.; Wolffram, S.; Rimbach, G. Effect of quercetin on inflammatory gene expression in mice liver in vivo—Role of redox factor 1, miRNA-122 and miRNA-125b. *Pharmacol. Res.* **2012**, *65*, 523–530. [CrossRef]

203. Mohamed, H.E.; Abo-ELmatty, D.M.; Salah, S.M.; Sakr, A.T. Ameliorative effect of grape seed extract on metabolic disorders caused by high fat diet induced obesity in rats by reversing the inrease inhepatic miR-33a and miR-122. *Afr. J. Pharm. Pharmacol.* **2016**, *10*, 699–708.

204. Zhao, X.J.; Yu, H.W.; Yang, Y.Z.; Wu, W.Y.; Chen, T.Y.; Jia, K.K.; Kang, L.L.; Jiao, R.Q.; Kong, L.D. Polydatin prevents fructose-induced liver inflammation and lipid deposition through increasing miR-200a to regulate Keap1/Nrf2 pathway. *Redox Biol.* **2018**, *18*, 124–137. [CrossRef] [PubMed]

205. Otton, R.; Bolin, A.P.; Ferreira, L.T.; Marinovic, M.P.; Rocha, A.L.S.; Mori, M.A. Polyphenol-rich green tea extract improves adipose tissue metabolism by down-regulating miR-335 expression and mitigating insulin resistance and inflammation. *J. Nutr. Biochem.* **2018**, *57*, 170–179. [CrossRef] [PubMed]

206. Gracia, A.; Miranda, J.; Fernández-Quintela, A.; Eseberri, I.; García-Lacarte, M.; Milagro, F.I.; Martínez, J.A.; Aguirre, L.; Portillo, M.P. Involvement of miR-539-5p in the inhibition of de novo lipogenesis induced by resveratrol in white adipose tissue. *Food Funct.* **2019**, *10*, 6970–6982. [CrossRef] [PubMed]

207. Tomé-Carneiro, J.; Larrosa, M.; Yáñez-Gascón, M.J.; Dávalos, A.; Gil-Zamoran, J.; González-Vez, M.; García-Almagro, F.J.; Ruiz Ros, J.A.; Tomás-Barberán, F.A.; Espin, J.C.; et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. *Pharmacol. Res.* **2013**, *72*, 69–82. [CrossRef]

208. Glässer, G.; Graefe, E.U.; Struck, F.; Veit, M.; Gebhardt, R. Comparison of antioxidative capacities and inhibitory effects on cholesterol biosynthesis of quercetin and potential metabolites. *Phytomedicine* **2002**, *9*, 33–40. [CrossRef]

209. Merfort, I.; Heilmann, J.; Weiss, M.; Pietta, P.; Gardana, C. Radical scavenger activity of three flavonoid metabolites studied by inhibition of chemiluminescence in human PMNs. *Planta Med.* **1996**, *62*, 289–292. [CrossRef]

210. Tang, Y.; Nakashima, S.; Saiki, S.; Myoi, Y.; Abe, N.; Kuwazuru, S.; Zhu, B.; Ashida, H.; Murata, Y.; Nakamura, Y. 3,4-Dihydroxyphenylacetic acid is a predominant biologically-active catabolite of quercetin glycosides. *Food Res. Int.* **2016**, *89*, 716–723. [CrossRef]

211. Liu, Y.; Kurita, A.; Nakashima, S.; Zhu, B.; Munemasa, S.; Nakamura, T.; Murata, Y.; Nakamura, Y. 3,4-Dihydroxyphenylacetic acid is a potential aldehyde dehydrogenase inducer in murine hepatoma Hepa1c1c7 cells. *Biochim. Biophys. Acta Biochem.** **2017**, *57*, 1978–1983. [CrossRef]
212. Monagas, M.; Khan, N.; Andres-Lacueva, C.; Urpi-Sarda, M.; Vazquez-Arell, M.; Lamuela-Raventos, R.M.; Estruch, R. Dihydroxylated phenolic acids derived from microbial metabolism reduce lipopolysaccharide-stimulated cytokine secretion by human peripheral blood mononuclear cells. Br. J. Nutr. 2009, 102, 201–206. [CrossRef]
213. Rechner, A.R.; Kroner, C. Anthocyanins and colonic metabolites of dietary polyphenols inhibit platelet function. Thromb. Res. 2005, 116, 327–334. [CrossRef] [PubMed]
214. Álvarez-Cillerós, D.; Ramos, S.; Goya, L.; Martín, M.A. Colonic metabolites from flavanols stimulate nitric oxide production in human endothelial cells and protect against oxidative stress-induced toxicity and endothelial dysfunction. Food Chem. Toxicol. 2018, 115, 88–97. [CrossRef] [PubMed]
215. Fernandez-Millan, E.; Ramos, S.; Alvarez, C.; Bravo, L.; Goya, L.; Martin, M.A. Microbial phenolic metabolites improve glucose-stimulated insulin secretion and protect pancreatic beta cells against tert-butyl hydroperoxide-induced toxicity via ERKs and PKC pathways. Food Chem. Toxicol. 2014, 66, 245–253. [CrossRef] [PubMed]
216. Carrasco-Pozo, C.; Gotteland, M.; Castillo, R.L.; Chen, C. 3,4-Dihydroxyphenylacetic acid, a microbiota-derived metabolite of quercetin, protects against pancreatic beta-cells dysfunction induced by high cholesterol. Exp. Cell Res. 2015, 334, 270–282. [CrossRef] [PubMed]
217. Rechner, A.R.; Smith, M.A.; Kuhnle, G.; Gibson, G.R.; Debnam, E.S.; Srai, S.K.S.; Moore, K.P.; Rice-Evans, C.A. Colonic metabolism of dietary polyphenols: Influence of structure on microbial fermentation products. Free Radical. Biol. Med. 2004, 36, 212–225. [CrossRef] [PubMed]
218. Winter, J.; Moore, L.H.; Dowell, V.R., Jr.; Bokkenheuser, V.D. C-ring cleavage of flavonoids by human intestinal bacteria. Appl. Environ. Microbiol. 1989, 55, 1203–1208. [CrossRef]
219. Schneider, H.; Simmering, R.; Hartmann, L.; Pföre, H.; Blaut, M. Degradation of quercetin-3-glucoside in gnotobiotic rats associated with human intestinal bacteria. J. Appl. Microbiol. 2000, 89, 1027–1037. [CrossRef]
220. Feng, X.; Li, Y.; Brobbey Oppong, M.; Qiu, F. Insights into the intestinal bacterial metabolism of flavonoids and the bioactivities of their microbe-derived ring cleavage metabolites. Drug Metab. Rev. 2018, 50, 343–356. [CrossRef] [PubMed]
221. Hanske, L.; Loh, G.; Sczesny, S.; Blaut, M.; Braune, A. The Bioavailability of Apigenin-7-Glucoside Is Influenced by Human Intestinal Microbiota in Rats. J. Nutr. 2009, 139, 1095–1102. [CrossRef]
222. Labib, S.; Erb, A.; Kraus, M.; Wickert, T.; Richling, E. The pig caecum model: A suitable tool to study the intestinal metabolism of flavonoids. Mol. Nutr. Food Res. 2004, 48, 326–332. [CrossRef]
223. Zou, W.; Luo, Y.; Liu, M.; Chen, S.; Wang, S.; Nie, Y.; Cheng, G.; Su, W.; Zhang, K. Human intestinal microbial metabolism of naringin. Eur. J. Drug Metab. Pharmacokinet. 2015, 40, 363–367. [CrossRef]
224. Yuan, J.-P.; Wang, J.-H.; Liu, X. Metabolism of dietary soy isoflavones to equol by human intestinal microorganisms—Implications for health. Mol. Nutr. Food Res. 2007, 51, 765–781. [CrossRef] [PubMed]
225. Sekikawa, A.; Ihara, M.; Lopez, O.; Kakuta, C.; Lopresti, B.; Higashiyama, A.; Aizenstein, H.; Chang, Y.F.; Mathis, C.; Miyamoto, Y.; et al. Effect of S-equol and Soy Isoflavones on Heart and Brain. Curr. Cardiol. Rev. 2019, 15, 114–135. [CrossRef] [PubMed]
226. Choi, E.J.; Kim, G.H. The antioxidant activity of daidzein metabolites, O-desmethylangolensin and equol, in HepG2 cells. Mol. Med. Rep. 2014, 9, 328–332. [CrossRef] [PubMed]
227. Schneider, H.; Blaut, M. Anaerobic degradation of flavonoids by Eubacterium ramulus. Arch. Microbiol. 2000, 173, 71–75. [CrossRef] [PubMed]
228. Tzounis, X.; Vulevic, J.; Kuhnle, G.G.C.; George, T.; Leonczak, J.; Gibson, G.R.; Kwik-Uribe, C.; Spencer, J.P.E. Flavanol monomer-induced changes to the human faecal microflora. Br. J. Nutr. 2008, 99, 782–792. [CrossRef] [PubMed]
229. Mena, P.; Bresciani, L.; Brindani, N.; Ludwig, I.; Pereira Caro, G.; Angelino, D.; Llorach, R.; Calani, L.; Brighenti, F.; Clifford, M.; et al. Phenyl-y-valerolactones and phenylvaleric acids, the main colonic metabolites of flavan-3-ols: Synthesis, analysis, bioavailability, and bioactivity. Nat. Prod. Rep. 2019, 36, 714–752. [CrossRef] [PubMed]
230. Ottaviani, J.L.; Borges, G.; Momma, T.Y.; Spencer, J.P.E.; Keen, C.L.; Crozier, A.; Schroeter, H. The metabolome of [2-14C](-)-epicatechin in humans: Implications for the assessment of efficacy, safety, and mechanisms of action of polyphenolic bioactives. Sci. Rep. 2016, 6, 29034. [CrossRef]
231. Mele, L.; Carobbio, S.; Brindani, N.; Curti, C.; Rodriguez-Cuenca, S.; Bidault, G.; Mena, P.; Zanotti, I.; Vacca, M.; Vidal-Puig, A.; et al. Phenyl-γ-valerolactones, flavan-3-ol colonic metabolites, protect brown adipocytes from oxidative stress without affecting their differentiation or function. *Mol. Nutr. Food Res.* 2017, 61, 1700074. [CrossRef]

232. Lambert, J.D.; Rice, J.E.; Hong, J.; Hou, Z.; Yang, C.S. Synthesis and biological activity of the tea catechin metabolites, M4 and M6 and their methoxy-derivatives. *Bioorg. Med. Chem. Lett.* 2005, 15, 873–876. [CrossRef]

233. Uhlenhut, K.; Högger, P. Facilitated cellular uptake and suppression of inducible nitrite oxide synthase by a metabolite of maritime pine bark extract (Pycnogetol). *Free Radic. Biol. Med.* 2012, 53, 305–313. [CrossRef]

234. Lee, C.C.; Kim, J.H.; Kim, J.S.; Oh, Y.S.; Han, S.M.; Park, J.H.Y.; Lee, K.W.; Lee, C.Y. 5-(3',4'-Dihydroxyphenyl-gamma-valerolactone), a Major Microbial Metabolite of Proanthocyanidin, Attenuates THP-1 Monocyte-Endothelial Adhesion. *Int. J. Mol. Sci.* 2017, 18, 1363. [CrossRef] [PubMed]

235. Takagaki, A.; Nanjo, F. Effects of Metabolites Produced from (−)-Epigallocatechin Gallate by Rat Intestinal Bacteria on Angiotensin I-Converting Enzyme Activity and Blood Pressure in Spontaneously Hypertensive Rats. *J. Agric. Food Chem.* 2015, 63, 8262–8266. [CrossRef] [PubMed]

236. Van Rynenant, E.; Grootaert, C.; Beerens, K.; Needs, P.W.; Kroon, P.A.; Kerimi, A.; Williamson, G.; Miladinović, B.; Kostić, M.; Šavikin, K.; Đorđević, B.; Mihajilov-Krstev, T.; Živanović, S.; Kitić, D. Chemical Profile and Antioxidative and Antimicrobial Activity of Juices and Extracts of 4 Black Currents Varieties (*Ribes nigrum* L.). *J. Food Sci.* 2014, 79, C301–C309. [CrossRef]

237. Aura, A.M.; Martin-Lopez, P.; O’Leary, K.A.; Williamson, G.; Oksman-Caldentey, K.M.; Poutanen, K.; Santos-Buelga, C. In vitro metabolism of anthocyanins by human gut microflora. *Eur. J. Nutr.* 2005, 44, 133–142. [CrossRef]

238. Vitaglione, P.; Donnarumma, G.; Napolitano, A.; Galvano, F.; Gallo, A.; Scalfi, L.; Fogliano, V. Protocatechuic acid is the major human metabolite of cyanidin-glucosides. *J. Nutr.* 2007, 137, 2043–2048. [CrossRef] [PubMed]

239. Williamson, G.; Clifford, M.N. Colonic metabolites of berry polyphenols: The missing link to biological activity? *Br. J. Nutr.* 2010, 104 (Suppl. S3), S48–S66. [CrossRef]

240. Gowd, V.; Bao, T.; Wang, L.; Huang, Y.; Chen, S.; Zheng, X.; Cui, S.; Chen, W. Antioxidant and antidiabetic activity of blackberry after gastrointestinal digestion and human gut microbiota fermentation. *Food Chem.* 2018, 269, 618–627. [CrossRef]

241. Ho, G.T.; Wangensteen, H.; Barsett, H. Elderberry and Elderflower Extracts, Phenolic Compounds, and Metabolites and Their Effect on Complement, RAW 264.7 Macrophages and Dendritic Cells. *Int. J. Mol. Sci.* 2017, 18, 584. [CrossRef]

242. Andreasen, M.F.; Kroon, P.A.; Williamson, G.; Garcia-Conesa, M.T. Esterase activity able to hydrolyze dietary antioxidant hydroxycinnamates is distributed along the intestine of mammals. *J. Agric. Food Chem.* 2001, 49, 5679–5684. [CrossRef]

243. Couteau, D.; McCartney, A.L.; Gibson, G.R.; Williamson, G.; Faulds, C.B. Isolation and characterization of human colonic bacteria able to hydrolyse chlorogenic acid. *Eur. J. Nutr.* 2007, 46, 1700074. [CrossRef] [PubMed]

244. Couteau, D.; McCartney, A.L.; Gibson, G.R.; Williamson, G.; Faulds, C.B. Isolation and characterization of human colonic bacteria able to hydrolyse chlorogenic acid. *Eur. J. Nutr.* 2007, 46, 1700074. [CrossRef] [PubMed]

245. González-Barrio, R.; Borges, G.; Mullen, W.; Crozier, A. Bioavailability of anthocyanins and ellagitannins following consumption of raspberries by healthy humans and subjects with an ileostomy. *J. Agric. Food Chem.* 2010, 58, 3933–3939. [CrossRef]

246. Inno, T.; Tashima, K.; Umeda, M.; Ogawa, Y.; Takeeda, M.; Takata, K.; Takeuchi, K. Effect of ellagic acid on gastric damage induced in ischemic rat stomachs following ammonia or reperfusion. *Life Sci.* 2002, 70, 1139–1150. [CrossRef]

247. Yu, Y.M.; Wang, Z.H.; Liu, C.H.; Chen, C.S. Ellagic acid inhibits IL-1beta-induced cell adhesion molecule expression in human umbilical vein endothelial cells. *Br. J. Nutr.* 2007, 97, 692–698. [CrossRef]
249. Chang, W.C.; Yu, Y.M.; Chiang, S.Y.; Tseng, C.Y. Ellagic acid suppresses oxidised low-density lipoprotein-induced aortic smooth muscle cell proliferation: Studies on the activation of extracellular signal-regulated kinase 1/2 and proliferating cell nuclear antigen expression. *Br. J. Nutr.* 2008, 99, 709–714. [CrossRef]

250. Ishimoto, H.; Tai, A.; Yoshimura, M.; Amakura, Y.; Yoshida, T.; Hatano, T.; Ito, H. Antioxidative properties of functional polyphenols and their metabolites assessed by an ORAC assay. *Biosci. Biotechnol. Biochem.* 2012, 76, 395–399. [CrossRef]

251. Komatsu, W.; Kishi, H.; Yagasaki, K.; Ohhira, S. Urolithin A attenuates pro-inflammatory mediator production by suppressing PI3-K/Akt/NF-κB and JNK/AP-1 signaling pathways in lipopolysaccharide-stimulated RAW264 macrophages: Possible involvement of NAPDH oxidase-derived reactive oxygen species. *Eur. J. Pharmacol.* 2018, 833, 411–424. [CrossRef]

252. Tang, L.; Mo, Y.; Li, Y.; Zhong, Y.; He, S.; Zhang, Y.; Tang, Y.; Fu, S.; Wang, X.; Chen, A. Urolithin A alleviates myocardial ischemia/reperfusion injury via PI3K/Akt pathway. *Biochem. Biophys. Res. Commun.* 2017, 486, 774–780. [CrossRef] [PubMed]

253. González-Sarrias, A.; Larrosa, M.; Tomás-Barberán, F.A.; Dolar, P.; Espín, J.C. NF-κB-dependent anti-inflammatory activity of urolithins, gut microbiota ellagic acid-derived metabolites, in human colonic fibroblasts. *Br. J. Nutr.* 2010, 104, 503–512. [CrossRef] [PubMed]

254. Giménez-Bastida, J.A.; González-Sarrias, A.; Larrosa, M.; Tomás-Barberán, F.; Espín, J.C.; García-Conesa, M.T. Ellagitannin metabolites, urolithin A glucuronide and its aglycone urolithin A, ameliorate TNF-α-induced inflammation and associated molecular markers in human aortic endothelial cells. *Mol. Nutr. Food Res.* 2012, 56, 784–796. [CrossRef] [PubMed]

255. Corsini, E.; Dell’Aghi, M.; Facchi, A.; De Fabiani, E.; Lucchi, L.; Boraso, M.S.; Marinovich, M.; Galli, C.L. Enteroediol and enterolactone modulate the immune response by acting on nuclear factor-kappaB (NF-κB) signaling. *J. Agric. Food Chem.* 2010, 58, 6678–6684. [CrossRef] [PubMed]

256. Prasad, K. Antioxidant Activity of Secoisolariciresinol Diglucoside-derived Metabolites, Secoisolariciresinol, Enteroediol, and Enterolactone. *Int. J. Angiol.* 2000, 9, 220–225. [CrossRef] [PubMed]

257. Kitts, D.D.; Yuan, Y.V.; Wijewickreme, A.N.; Thompson, L.U. Antioxidant activity of the flaxseed lignan secoisolariciresinol diglucoside and its mammalian lignan metabolites enterodiol and enterolactone. *Mol. Cell. Biochem.* 1999, 202, 91–100. [CrossRef] [PubMed]

258. Heinonen, S.; Nurmi, T.; Liukkonen, K.; Poutanen, K.; Wäähälä, K.; Deyama, T.; Nishibe, S.; Adlercreutz, H. In Vitro Metabolism of Plant Lignans: New Precursors of Mammalian Lignans Enterolactone and Enterodiol. *J. Agric. Food Chem.* 2001, 49, 3178–3186. [CrossRef]

259. Springer, M.; Moco, S. Resveratrol and Its Human Metabolites-Effects on Metabolic Health and Obesity. *Nutrients* 2019, 11, 143. [CrossRef]

260. Lu, D.L.; Ding, D.J.; Yan, W.J.; Li, R.R.; Dai, F.; Wang, Q.; Yu, S.S.; Li, Y.; Jin, X.L.; Zhou, B. Influence of glucuronidation and reduction modifications of resveratrol on its biological activities. *ChemBiochem* 2013, 14, 1094–1104. [CrossRef]

261. Bode, L.M.; Bunzel, D.; Huch, M.; Cho, G.S.; Ruhland, D.; Bunzel, M.; Bub, A.; Franz, C.M.; Kulling, S.E. In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. *Am. J. Clin. Nutr.* 2013, 97, 295–309. [CrossRef] [PubMed]

262. Rodriguez-Mateos, A.; Heiss, C.; Borges, G.; Crozier, A. Berry (poly)phenols and cardiovascular health. *J. Agric. Food Chem.* 2014, 62, 3842–3851. [CrossRef] [PubMed]
266. Su, K.-Y.; Yu, C.Y.; Chen, Y.-P.; Hua, K.-F.; Chen, Y.-L.S. 3,4-Dihydroxytoluene, a metabolite of rutin, inhibits inflammatory responses in lipopolysaccharide-activated macrophages by reducing the activation of NF-κB signaling. *BMC Complement Altern. Med.* 2014, 14, 1–9. [CrossRef] [PubMed]

267. Ozdal, T.; Sela, D.A.; Xiao, J.; Boyacioglu, D.; Chen, F.; Capanoglu, E. The Reciprocal Interactions between Polyphenols and Gut Microbiota and Effects on Bioaccessibility. *Nutrients* 2016, 8, 78. [CrossRef] [PubMed]

268. Manach, C.; Williamson, G.; Morand, C.; Scalbert, A.; Remesy, C. Bioavailability and bioefficacy of polyphenols in humans. I. Review of 97 bioavailability studies. *Am. J. Clin. Nutr.* 2005, 81, 2305–2425. [CrossRef] [PubMed]

269. Rietjens, I.M.C.M.; Louisse, J.; Beekmann, K. The potential health effects of dietary phytoestrogens. *Br. J. Pharmacol.* 2017, 174, 1263–1280. [CrossRef]

270. Sánchez-Calvo, J.M.; Rodríguez-Iglesias, M.A.; Molinillo, J.M.G.; Macías, F.A. Soy isoflavones and their relationship with microbiota: Beneficial effects on human health in equol producers. *Phytochem. Res.* 2013, 12, 979–1000. [CrossRef]

271. Tousen, Y.; Uehara, M.; Abe, F.; Kimira, Y.; Ishimi, Y. Effects of short-term fructooligosaccharide intake on equol production in Japanese postmenopausal women consuming soy isoflavone supplements: A pilot study. *Nutr. J.* 2013, 12, 127. [CrossRef]

272. Setchell, K.D.; Brown, N.M.; Summer, S.; King, E.C.; Heubi, J.E.; Cole, S.; guy, T.; Hokin, B. Dietary factors influence production of the soy isoflavone metabolite s-(−)equol in healthy adults. *J. Nutr.* 2013, 143, 1950–1958. [CrossRef]

273. Usui, T.; Tochiya, M.; Sasaki, Y.; Muranaka, K.; Yamakage, H.; Himeno, A.; Shimatsu, A.; Inaguma, A.; Ueno, T.; Uchiyama, S.; et al. Effects of natural S-equol supplements on overweight or obesity and metabolic syndrome in the Japanese, based on sex and equol status. *Clin. Endocrinol.* 2013, 78, 365–372. [CrossRef]

274. Yoshikata, R.; Myint, K.Z.Y.; Ohta, H. Effects of fructose intake on serum lipids and uric acid in adults in Guangzhou, China. *Br. J. Nutr.* 2010, 104, 118–124. [CrossRef]

275. Liu, Z.M.; Ho, S.C.; Chen, Y.M.; Liu, J.; Woo, J. Cardiovascular risks in relation to daidzein-metabolizing phenotypes among Chinese postmenopausal women. *PLoS ONE* 2014, 9, e87861. [CrossRef]

276. Guo, K.; Zhang, B.; Chen, C.; Uchiyama, S.; Ueno, T.; Chen, Y.; Su, Y. Daidzein-metabolising phenotypes in relation to serum lipids and uric acid in adults in Guangzhou, China. *Br. J. Nutr.* 2010, 104, 118–124. [CrossRef]

277. Shi, L.; Ryan, H.H.; Jones, E.; Simas, T.A.M.; Lichtenstein, A.H.; Sun, Q.; Hayman, L.L. Urinary isoflavone concentrations are inversely associated with cardiometabolic risk markers in pregnant U.S. women. *J. Nutr.* 2014, 144, 344–351. [CrossRef]

278. Frankenfeld, C.L.; Atkinson, C.; Wåhälå, K.; Lampe, J.W. Obesity prevalence in relation to gut microbial environments capable of producing equol or O-desmethylangolensin from the isoflavone daidzein. *Eur. J. Clin. Nutr.* 2014, 68, 526–530. [CrossRef]

279. Pérez-Jiménez, J.; Feiz, L.; Touvier, M.; Arnault, N.; Manach, C.; Hercberg, S.; Galan, P.; Scalbert, A. Dietary intake of 337 polyphenols in French adults. *Am. J. Clin. Nutr.* 2011, 93, 1220–1228. [CrossRef]

280. Del Rio, D.; Rodriguez-Mateos, A.; Spencer, J.P.E.; Tognolini, M.; Borges, G.; Crozier, A. Dietary (poly)phenolics in human health: Structures, bioavailability, and evidence of protective effects against chronic diseases. *Antioxid. Redox Sign.* 2013, 18, 1818–1892. [CrossRef]

281. Sansone, R.; Rodriguez-Mateos, A.; Heuel, J.; Falk, D.; Schuler, D.; Wagstaft, R.; Kuhnle, G.G.C.; Spencer, J.P.E.; Schroeter, H.; Merx, M.W.; et al. Cocoa flavanol intake improves endothelial function and Framingham Risk Score in healthy men and women: A randomised, controlled, double-masked trial: The Flaviola Health Study. *Br. J. Nutr.* 2015, 114, 1246–1255. [CrossRef] [PubMed]
285. Stote, K.S.; Clevendence, B.A.; Novotny, J.A.; Henderson, T.; Radecki, S.V.; Baer, D.J. Effect of cocoa and green tea on biomarkers of glucose regulation, oxidative stress, inflammation and hemostasis in obese adults at risk for insulin resistance. *Eur. J. Clin. Nutr.* 2012, 66, 1153–1159. [CrossRef] [PubMed]

286. Castello, F.; Costabile, G.; Bresciani, L.; Tassotti, M.; Naviglio, D.; Luongo, D.; Ciciola, P.; Vitale, M.; Vetranì, C.; Galaverna, G.; et al. Bioavailability and pharmacokinetic profile of grape pomace phenolic compounds in humans. *Arch. Biochem. Biophys.* 2018, 646, 1–9. [CrossRef] [PubMed]

287. Hansson, G.K.; Libby, P. The immune response in atherosclerosis: A double-edged sword. *Nat. Rev. Immunol.* 2006, 6, 508–519. [CrossRef] [PubMed]

288. Rodriguez-Mateos, A.; Feliciano, R.P.; Boeres, A.; Weber, T.; Dos Santos, C.N.; Ventura, M.R.; Heiss, C. Cranberry (poly)phenol metabolites correlate with improvements in vascular function: A double-blind, randomized, controlled, dose-response, crossover study. *Mol. Nutr. Food Res.* 2016, 60, 2130–2140. [CrossRef]

289. Sasaki, G.Y.; Li, J.; Cichon, M.J.; Riedl, K.M.; Kopec, R.E.; Bruno, R.S. Green Tea Extract Treatment in Obese Mice with Nonalcoholic Steatohepatitis Restores the Hepatic Metabolome in Association with Limiting Endotoxemia-TLR4-NFκB-Mediated Inflammation. *Mol. Nutr. Food Res.* 2019, 63, e1900811. [CrossRef]

290. Panchal, S.K.; Ward, L.; Brown, L. Ellagic acid attenuates high-carbohydrate, high-fat diet-induced metabolic syndrome in rats. *Eur. J. Nutr.* 2013, 52, 559–568. [CrossRef]

291. Rani, U.P.; Kesavan, R.; Ganugula, R.; Avaneesh, T.; Kumar, U.P.; Reddy, G.B.; Dixit, M. Ellagic acid inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and prevents atheroma formation in streptozotocin-induced diabetic rats. *J. Nutr. Biochem.* 2013, 24, 1830–1839. [CrossRef]

292. Tomás-Barberán, F.A.; García-Villalba, R.; González-Sarrías, A.; Selma, M.V.; Espín, J.C. Ellagic acid metabolism by human gut microbiota: Consistent observation of three urolithin phenotypes in intervention trials, independent of food source, age, and health status. *J. Agric. Food Chem.* 2014, 62, 6535–6538. [CrossRef]

293. Larrosa, M.; González-Sarrías, A.; Yañez-Gascón, M.J.; Selma, M.V.; Azorin-Ortuño, M.; Toti, S.; Tomás-Barberán, F.; Dolar, P.; Espín, J.C. Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-A in a colitis rat model and the effect of colon inflammation on phenolic metabolism. *J. Nutr. Biochem.* 2010, 21, 717–725. [CrossRef]

294. Ishimoto, H.; Shibata, R.; Sugimoto, Y.; Tai, A.; Hatano, T. In vivo anti-inflammatory and antioxidant properties of ellagitannin metabolite urolithin A. *Bioorg. Med. Chem. Lett.* 2011, 21, 5901–5904. [CrossRef] [PubMed]

295. Kawai, Y. Immunochemical detection of food-derived polyphenols in the aorta: Macrophages as a major target underlying the anti-atherosclerotic activity of polyphenols. *Biosci. Biotechnol. Biochem.* 2011, 75, 609–617. [CrossRef] [PubMed]

296. Selma, M.V.; González-Sarrías, A.; Salas-Salvadó, J.; Andrés-Lacueva, C.; Alasalvar, C.; Òrem, A.; Tomás-Barberán, F.A.; Espín, J.C. The gut microbiota metabolism of pomegranate or walnut ellagitannins yields two urolithin-metabotypes that correlate with cardiometabolic risk biomarkers: Comparison between normoweight, overweight-obesity and metabolic syndrome. *Arch. Biochem. Biophys.* 2018, 66, 71. [CrossRef]

297. Gutiérrez-Diaz, I.; Fernández-Navarro, T.; Salazar, N.; Bartolomé, B.; Moreno-Arríbas, M.V.; López, P.; Suárez, A.; de Los Reyes-Gavilán, C.G.; Guimerónd, M.; González, S. Could Fecal Phenylacetic and Phenylpropionic Acids Be Used as Indicators of Health Status? *J. Agric. Food Chem.* 2018, 66, 10438–10446. [CrossRef] [PubMed]

298. Yang, J.; Guo, Y.; Henning, S.M.; Chan, B.; Long, J.; Zhong, J.; Acin-Perez, R.; Petcherski, A.; Shirihai, O.; Heber, D.; et al. Ellagic Acid and Its Microbial Metabolite Urolithin A Alleviate Diet-Induced Insulin Resistance in Mice. *Mol. Nutr. Food Res.* 2020, 64, e2000091. [CrossRef]

299. Xia, B.; Shi, X.C.; Xie, B.C.; Zhu, M.Q.; Chen, Y.; Chu, X.Y.; Cai, G.H.; Liu, M.; Yang, S.Z.; Mitchell, G.A.; et al. Urolithin A exerts antiobesity effects through enhancing adipose tissue thermogenesis in mice. *PLoS Biol.* 2020, 18, e3000688. [CrossRef]

300. Adolphé, J.L.; Whiting, S.J.; Juurlink, B.H.; Thorpe, L.U.; Alcorn, J. Health effects with consumption of the flax lignan secoisolariciresinol diglucoside. *Br. J. Nutr.* 2010, 103, 929–938. [CrossRef]

301. Imran, M.; Ahmad, N.; Anjum, F.M.; Khan, M.K.; Mushtaq, Z.; Nadeem, M.; Hussain, S. Potential protective properties of flax lignan secoisolariciresinol diglucoside. *Nutr. J.* 2015, 14, 71. [CrossRef]

302. Zhang, W.; Wang, X.; Liu, Y.; Tian, H.; Flickinger, B.; Empie, M.W.; Sun, S.Z. Dietary flaxseed lignan extract lowers plasma cholesterol and glucose concentrations in hypercholesterolaemic subjects. *Br. J. Nutr.* 2008, 99, 1301–1309. [CrossRef]
303. Prasad, K. Secoisolariciresinol diglucoside from flaxseed delays the development of type 2 diabetes in Zucker rat. *J. Lab. Clin. Med.* 2001, 138, 32–39. [CrossRef]

304. Kottke, T.E.; Ogwang, Z.; Smith, J.C. Reasons for not meeting coronary artery disease targets of care in ambulatory practice. *Perm. J.* 2010, 14, 12–16. [CrossRef] [PubMed]

305. Durazzo, A.; Lucarini, M.; Camilli, E.; Marconi, S.; Gabrielli, P.; Lisciani, S.; Gambelli, L.; Aguzzi, A.; Novellino, E.; Santini, A.; et al. Dietary Lignans: Definition, Description and Research Trends in Databases Development. *Molecules* 2018, 23, 3251. [CrossRef]

306. Corona, G.; Kreimes, A.; Barone, M.; Turroni, S.; Brigidi, P.; Keleszade, E.; Costabile, A. Impact of lignans in oilseed mix on gut microbiome composition and enterolignan production in younger healthy and premenopausal women: An in vitro pilot study. *Microb. Cell Fact.* 2020, 19, 82. [CrossRef] [PubMed]

307. Brito, A.F.; Zang, Y. A Review of Lignan Metabolism, Milk Enterolactone Concentration, and Antioxidant Status of Dairy Cows Fed Flaxseed. *Molecules* 2018, 24, 41. [CrossRef] [PubMed]

308. Rienks, J.; Barbaresko, J.; Nöthlings, U. Association of Polyphenol Biomarkers with Cardiovascular Disease and Mortality Risk: A Systematic Review and Meta-Analysis of Observational Studies. *Nutrients* 2017, 9, 415. [CrossRef]

309. Sun, Q.; Wedick, N.M.; Pan, A.; Townsend, M.K.; Cassidy, A.; Franke, A.A.; Rimm, E.B.; Hu, F.B.; van Dam, R.M. Gut microbiota metabolites of dietary lignans and risk of type 2 diabetes: A prospective investigation in two cohorts of U.S. women. *Diabet. Care* 2014, 37, 1287–1295. [CrossRef]

310. Struja, T.; Richard, A.; Linseisen, J.; Eichholzer, M.; Rohrmann, S. The association between urinary phytoestrogen excretion and components of the metabolic syndrome in NHANES. *Eur. J. Nutr.* 2014, 53, 1371–1381. [CrossRef]

311. Peñalvo, J.L.; López-Romero, P. Urinary enterolignan concentrations are positively associated with serum HDL cholesterol and negatively associated with serum triglycerides in U.S. adults. *J. Nutr.* 2012, 142, 751–756. [CrossRef]

312. Baur, J.A.; Sinclair, D.A. Therapeutic potential of resveratrol: The in vivo evidence. *Nat. Rev. Drug Discov.* 2006, 5, 493–506. [CrossRef]

313. Alberdi, G.; Rodriguez, V.M.; Miranda, J.; Macarulla, M.T.; Churrucha, I.; Portillo, M.P. Thermogenesis is involved in the body-fat lowering effects of resveratrol in rats. *Food Chem.* 2013, 141, 1530–1535. [CrossRef]

314. Szkudelski, T.; Szkudelska, K. Resveratrol and diabetes: From animal to human studies. *Biochim. Biophys. Acta* 2015, 1852, 1145–1154. [CrossRef] [PubMed]

315. Ménendez-del Villar, M.; González-Ortiz, M.; Martínez-Abundis, E.; Pérez-Rubio, K.G.; Lizárraga-Valdez, R. Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. *Metab. Syndr. Relat. Disord.* 2014, 12, 497–501. [CrossRef] [PubMed]

316. Timmers, S.; Konings, E.; Bilet, L.; Houtkooper, R.H.; van de Weijer, T.; Goossens, G.H.; Hoeks, J.; van der Krieken, S.; Ryu, D.; Kersten, S.; et al. Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. *Cell Metab.* 2011, 14, 612–622. [CrossRef] [PubMed]

317. Javkhedkar, A.A.; Quiroz, Y.; Rodriguez-Iturbe, B.; Vaziri, N.D.; Lokhandwala, M.F.; Banday, A.A. Resveratrol restored Nrf2 function, reduced renal inflammation, and mitigated hypertension in spontaneously hypertensive rats. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* 2015, 308, R840–R846. [CrossRef]

318. Dolinsky, V.W.; Chakrabarti, S.; Pereira, T.J.; Oka, T.; Levasseur, J.; Beker, D.; Zordoky, B.N.; Morton, J.S.; Nagendran, J.; Lopaschuk, G.D.; et al. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. *Biochim. Biophys. Acta* 2013, 1832, 1723–1733. [CrossRef] [PubMed]

319. Walker, J.M.; Eckardt, P.; Aleman, J.O.; da Rosa, J.C.; Liang, Y.; Iizumi, T.; Exheve, S.; Bleser, M.J.; Breslow, J.L.; Holt, P.R. The effects of trans-resveratrol on insulin resistance, inflammation, and microbiota in men with the metabolic syndrome: A pilot randomized, placebo-controlled clinical trial. *J. Clin. Transl. Res.* 2019, 4, 122–135. [PubMed]

320. Wenzel, E.; Soldo, T.; Erbersdobler, H.; Somoza, V. Bioactivity and metabolism of trans-resveratrol orally administered to Wistar rats. *Mol. Nutr. Food Res.* 2005, 49, 482–494. [CrossRef]

321. Boocock, D.J.; Patel, K.R.; Faust, G.E.; Normolle, D.P.; Marczylo, T.H.; Crowell, J.A.; Brenner, D.E.; Booth, T.D.; Gescher, A.; Steward, W.P. Quantitation of trans-resveratrol and detection of its metabolites in human plasma and urine by high performance liquid chromatography. *J. Chromatogr. B Analyt. Technol. Biomed. Life Sci.* 2007, 848, 182–187. [CrossRef]
322. Walle, T.; Hsieh, F.; DeLegge, M.H.; Oatis, J.E., Jr.; Walle, U.K. High absorption but very low bioavailability of oral resveratrol in humans. *Drug. Metab. Dispos.* **2004**, *32*, 1377–1382. [CrossRef]

323. Azorín-Ortuño, M.; Yáñez-Gascón, M.J.; Vallejo, F.; Pallarés, F.J.; Larrosa, M.; Lucas, R.; Morales, J.C.; Tomás-Barberán, F.A.; García-Conesa, M.T.; Espín, J.C. Metabolites and tissue distribution of resveratrol in the pig. *Mol. Nutr. Food Res.* **2011**, *55*, 1154–1168. [CrossRef]

© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).